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ABSTRACT 
MELANIE A. MOSER 
A Descriptive Review of Balamuthia and Non-Keratitis Acanthamoeba Cases in the 
United States, 1955-2009 
(Under the direction of Richard Rothenberg, Professor) 
 
Free-living amebae are ubiquitous in the environment and occasionally invade and 
parasitize host tissues causing illness in humans.  Despite possibly frequent exposure to 
these organisms, infection is rare and why some people, healthy or not, end up with 
illness and others do not is still unclear.  Human infections are rare; when illness does 
occur, it is often fatal.  Only two papers have examined data from the literature and cases 
reported to the Centers for Disease Control and Prevention, and both were published over 
twenty years ago.  The purpose of this study is to better document the epidemiology of 
Balamuthia and non-keratitis Acanthamoeba, give insight into trends of these infections 
over time, and contribute to the scientific and medical community by producing the only 
comprehensive review of all Balamuthia and non-keratitis Acanthamoeba cases in the 
United States from 1955 through 2009.  This study also examines cases that have 
survived in an attempt to determine if there is evidence for the effectiveness of a 
particular treatment regimen.  Only a small number of patients have survived these 
infections, so any evidence for a successful course of treatment could be crucial for future 
cases. 
 
INDEX WORDS: free-living amebae, Balamuthia mandrillaris, Acanthamoeba spp., 
non-keratitis Acanthamoeba
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 CHAPTER I: INTRODUCTION 
Background 
Free-living amebae are ubiquitous in the environment and occasionally invade 
and parasitize host tissues causing illness in humans.1,2  Although human infections are 
rare, when illness does occur, it is often fatal.  There are four genera of free-living 
amebae known to infect humans.2  Naegleria fowleri, which can cause primary amebic 
meningoencephalitis (PAM), is described in the media as the “brain-eating ameba”3,4 and 
news reports of infections with this organism have likely raised awareness of free-living 
amebae.  Other free-living amebae, such as Balamuthia mandrillaris and Acanthamoeba 
spp. can cause granulomatous amebic encephalitis (GAE), an infection of the central 
nervous system.  Although there is only one species of Balamuthia known to infect 
humans, B. mandrillaris, there are multiple species of Acanthamoeba, at least eight, that 
can cause human infection.  Acanthamoebiasis and balamuthiasis can manifest as 
disseminated infections throughout the body or localized in an area of the body, often 
affecting the brain, skin, and/or sinuses, as well as other organs such as the lungs, liver, 
kidneys or lymph nodes, either independently or in combination.  Acanthamoeba spp. can 
also cause keratitis, which may threaten an infected person’s vision by causing ulceration 
of the cornea, diminished sight, or even blindness.  Sappinia diploidea also has been 
identified as the cause of one reported case of encephalitis.1 
Naegleria fowleri has been isolated from warm freshwater, geothermal waters, 
soil, sewage, and unchlorinated or minimally chlorinated swimming pools.5,6  Likewise 
Acanthamoeba spp. have been found in soil, sewage, swimming pools, and freshwater but 
1 
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have also been identified in hot tubs, sea or brackish water, heating/ventilating/air 
conditioning (HVAC) units, dialysis machines, contact lens solutions, and intra-uterine 
devices (IUDs).6  Balamuthia mandrillaris is found in soil.7,8  Balamuthia might also be 
present in freshwater; there have been reports of Balamuthia GAE in dogs that swam in 
ponds but there have been no reported human cases where the only potential exposure 
was swimming.9,10  Because these amebae naturally inhabit so many locations, it is likely 
that humans are frequently exposed to them.  Immunologic studies of N. fowleri, 
Acanthamoeba spp., and B. mandrillaris have shown that some humans have antibodies 
to them.1  Two serologic studies carried out in the United States showed that persons who 
had extensive contact with freshwater lakes had antibody response to N .fowleri.11  
Antibodies to B. mandrillaris and Acanthamoeba spp. have been demonstrated in healthy 
as well as hospitalized persons.1  Despite possibly frequent exposure, infection is rare and 
why some people, healthy or not, end up with illness and others do not is still unclear. 
Culbertson was the first to suggest that free-living amebae could possibly cause 
infection in humans and showed pathogenicity using animal models.2,12  Butt described 
the first U.S. cases of free-living ameba infection, PAM caused by N. fowleri, in 1966.13   
Less than ten years later in 1972, Jager and Stamm reported the first human case of 
Acanthamoeba disease, which occurred in the U.S, although it was another eight years 
before it was definitively recognized that Acanthamoeba was the causal agent not 
Hartmannella as was supposed in the original case report.14,15  Eventually several reports 
preceding the 1966 first report of free living ameba infection were retrospectively 
identified as cases of Acanthamoeba spp. as understanding of the organisms increased.2  
Recognition that Balamuthia (referred to as leptomyxid ameba at the time) was also a 
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cause of human infections came in 1990 with a report of cases of GAE due to 
leptomyxid; the first U.S. was later retrospectively identified as occurring in 1978.16 
N. fowleri primarily affects immunocompetent children and young adults and 
without treatment has a rapid clinical course resulting in death within 1 to 2 weeks after 
exposure.1  In 1980, Martinez was the first to note that Acanthamoeba is an opportunistic 
infection affecting persons with chronic illness.17  This characterization seems to remain 
true as most reviews consider it to be an infection that typically affects 
immunocompromised persons.1,2,17  It is thought that there is a subacute phase of 
infection and the timeframe has not been well characterized, but once the acute phase 
commences, the infection can be fatal within weeks.  B. mandrillaris has been reported to 
affect both immuncompromised and healthy individuals.1  Of note, recent reports of 
Balamuthia infection via organ transplantation raise concerns for the organ procurement 
community.18,19  The clinical course of balamuthiasis is thought to be the same as that of 
acanthamoebiasis.  Like Acanthamoeba, Balamuthia can also infect tissues outside the 
central nervous system.1  Unlike with Acanthamoeba and Naegleria, it has been reported 
that being of Hispanic ethnicity may be a risk factor for B. mandrillaris infection.1,20 
There are subtle differences in the routes of human infection among the free-
living amebae.  N. fowleri enter the nasal cavity, attach to the nasal mucosa, cross the 
nasal-brain (cribriform) barrier, and invade the brain.  This invasion results in 
hemorrhagic necrosis as the amebae lyse or ingest red blood cells and/or digest or destroy 
brain tissue through secretions in their food cups.1,11  Acanthamoeba spp. is thought to 
invade the body via the nasopharyngeal route, breaks in the skin, or by inhalation of 
cysts.  The organism also produces food cups and secretes enzymes that may aid its 
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spread throughout the body.  Balamuthia is thought to have some similarity to 
Acanthamoeba in its route of infection and its possession of particular enzymes that aid in 
its invasion process, but little is known about its pathogenesis.1 
Meningoencephalitis is the swelling of the brain and its membranes.  Butt first 
introduced the concept of primary amebic infection to differentiate between Entamoeba 
histolytica’s secondary infection of the brain (via the bloodstream) and Naegleria’s direct 
infection.11  Later, Martinez differentiated between the manifestations of free-living 
amebae infections caused by Acanthamoeba and Naegleria, particularly the changes 
occurring in the tissues of the brain, giving further distinguishing differences between 
PAM and GAE.  PAM was characterized as “severe acute necrotizing and hemorrhagic 
meningoencephalitis involving mainly the base of frontal lobes and posterior fossa” (p. 
570) with lesions located on the surface of the brainstem, cerebellum, and cerebral 
hemispheres.17  GAE’s characteristics included: leptomeninges with moderate amount of 
purulent exudate over most affected cortical areas, moderate to severe edema in the 
cerebral hemisphere, and “foci of encephalomalacic worsening associated with small 
areas of hemorrhagic necrosis in occipital, parietal, temporal, or (less often) frontal 
lobes” (p. 569).  GAE lesions vary in their location and composition.17 
Purpose of the Study 
There have been many case reports of free-living ameba infections in the United 
States, publications on diagnostic techniques and immunology, and reviews of the 
organisms; but there is still much to learn about the epidemiology and clinical course of 
these infections.  A few case reports and reviews have attempted to summarize a limited 
number of published cases of acanthamoebiasis and balamuthiasis,21,22 or have examined 
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specific aspects of these infections, such as case reports of Acanthamoeba GAE or 
Acanthamoeba rhinosinusitis among AIDS patients.23,24  Only two papers have examined 
data from the literature and cases reported to CDC, and both were published over twenty 
years ago.6,16  A recently published article concerning the epidemiology of primary 
amebic meningoencephalitis caused by Naegleria fowleri in the United States gives a 
comprehensive review of cases using multiple sources of information such as the Centers 
for Disease Control and Prevention’s (CDC) Free-Living Ameba (FLA) Laboratory case 
registry and Waterborne Disease and Outbreak Surveillance System, as well as the 
National Vital Statistics System, published case reports, and media reports.25  The 
descriptive analysis presented within this thesis is modeled on the methodology of the 
PAM epidemiology paper and will examine Balamuthia and non-keratitis Acanthamoeba 
cases in the United States from 1955 to 2009 by accessing the FLA Laboratory case 
registry and published case and media reports. 
The purpose of this study is to better document the epidemiology of Balamuthia 
and non-keratitis Acanthamoeba, give insight into trends of these infections over time, 
and contribute to the scientific and medical community by producing the only 
comprehensive review of all known U.S. cases of Balamuthia and non-keratitis 
Acanthamoeba through 2009.  Along with bringing about a better understanding of the 
characteristics of these cases, this study will also examine cases that have survived and 
attempt to determine if there is any evidence for a given treatment regimen as being 
particularly effective.  Only a small number of patients have survived these infections, 
and any evidence for a successful course of treatment could be crucial for future cases. 
Research questions 
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1. Are there any demographic characteristics that indicate commonality between 
cases and suggest that persons of a particular ethnicity or race are more pre-
disposed to infection?  In particular, does Balamuthia disproportionately affect 
persons of Hispanic ethnicity as suggested in the literature? 
2. Are there any presenting symptoms that are particular to acanthamoebiasis and 
balamuthiasis that would assist clinicians in early identification of free-living 
ameba infection? 
3. Are there any commonalities in the treatment regimen of those who survived? 
4. What is the time from onset of symptoms to death? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II: REVIEW OF THE LITERATURE 
There have been more than 60 case reviews or reports citing cases of non-keratitis 
Acanthamoeba disease and over 40 cases of Balamuthia disease in the United States 
published between 1960 and 2009.  The first case report of Acanthamoeba disease was 
published in 1960, five years after the actual case occurred, and was reported as a 
granuloma of the brain, likely due Endolimax williamsi.26  This same case was cited in 
several subsequent publications as Acanthamoeba granulomatous amebic encephalitis 
(GAE) upon retrospective review.6,17,21,27  The first case report of Balamuthia disease was 
published in 1974; although Balamuthia was not recognized as the causal agent at the 
time, it was reported as a case of free-living amebic meningoencephalitis that was not due 
to Naegleria or Acanthamoeba.28  The case was cited as Balamuthia GAE in subsequent 
publications.6,17,27  Appendix A has detailed tables of all published Acanthamoeba and 
Balamuthia case reports. 
Disseminated infections 
A review of the literature reveals Acanthamoeba disease manifests itself in 
various ways (disseminated, GAE, cutaneous, rhinosinusitis, osteomyelitis) as does 
Balamuthia (disseminated and GAE).  But unlike Acanthamoeba, disseminated 
balamuthiasis always involves the brain.  Disseminated Acanthamoeba disease was the 
most frequently reported manifestation of acanthamoebiasis in the United States, with 29 
cases published in the literature.  [See Appendix A, Table 1 for all disseminated 
acanthamoebiasis case references.]  The majority (n=19) of reported disseminated
7 
8 
 
infections were in patients who had human immunodeficiency virus (HIV) or who had 
acquired immune deficiency syndrome (AIDS).  [See cases 5-11, 13-19, 21, 22, 24, 25, 
and 28.]  While HIV/AIDS was the predominant cause for immunosuppression among 
case patients with disseminated acanthamoebiasis reported in the literature, it was 
followed by those with a previous medical history of organ transplantation and 
immunosuppressive drug therapy (n=4; cases 4, 23, 27, and 29) and bone marrow 
transplants due to cancer (n=3; cases 12, 20, 26).  One case was reported as having lupus 
and two case reports cited no known predisposing health factors (cases 3, 1, and 2 
respectively). 
The most common form of disseminated Acanthamoeba disease was a 
combination of skin and sinus infection (n=10; cases 5, 8, 11, 13-15, 21, 22, 24, 28), 
followed by cases with a combination of GAE and cutaneous infection (n=3; cases 6, 9, 
20).  There were two reports of patients with GAE, cutaneous, and lung disease (cases 3, 
29), two reports of patients with GAE and lung disease (cases 10, 26), and two cases with 
cutaneous infection and osteomyelitis (cases 17, 27).  The other disseminated 
manifestations varied greatly among the patients.  Those cases that included GAE and 
other manifestations were: GAE, cutaneous, and sinus (n=1; case 19); GAE and keratitis 
(n=1; case 1); GAE, lungs, and adrenals (n=1; case 12); GAE, cutaneous, and pulmonary 
hyaline membrane (n=1; case 4); and GAE, cutaneous, sinus, lymph nodes, thyroid, and 
adrenals (n=1; case 2).  Other disseminated cases included: cutaneous, lungs, and keratitis 
(n=1; case 7); cutaneous, lungs, heart, kidney, spleen, and lymph nodes (n=1; case 16); 
cutaneous, sinus, and osteomyelitis (n=1; case 18); cutaneous, liver, and bronchoaveolar 
lavage (n=1; case 23).  One case reported sinus and lung involvement (case 25). 
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The majority of the disseminated acanthamoebiasis cases were in adult males 
(n=18; cases 4-10, 13-15, 18, 19, 21, 22, 24-26, 29), and all children (<18 years of age) 
reported to have disseminated acanthamoebiasis were boys (n=4; cases 1, 11, 16, 17).  
Seven females were reported with disseminated disease (cases 2, 3, 12, 20, 23, 27, 28). 
Three reports noted that the patients were of Hispanic ethnicity (cases 2, 11, and 14) 
although two additional cases were perhaps of Hispanic ethnicity (cases 6 and 28), being 
described as Mexican American and Nicaraguan, respectively.  However, the other 26 
case reports failed to describe ethnicity, so an assessment of proportion of cases by 
ethnicity cannot be made.  Only two reports included information about possible 
environmental exposures and they were both water exposures, one from fishing on a 
freshwater lake (case 29) and one from wading in drainage ditches (case 1).  When 
timeframes were able to be determined, the number of days between suspected onset of 
symptoms and death ranged from 8 to 765 days (cases 1-3, 5, 6, 8, 10-13, 16, 19-23, 25, 
26, 29).  Three cases resolved their infections and did not die (cases 17, 23, 24) and eight 
did not have adequate information on the symptom onset/death timeframe to determine 
outcome status (cases 4, 7, 9, 14, 15, 18, 27, 28).  The number of days between 
hospitalization and death ranged from 2 to 120 days (cases 1-7, 9, 10, 14, 15, 18, 25, 26, 
27, 28).  Twelve cases did not have adequate information on the hospitalization/death 
timeframe (cases 7, 8, 11, 12, 13, 16, 17, 19, 20, 21, 22, 28).  Prognosis for those 
diagnosed with disseminated disease was poor, with 25 cases having died either from 
Acanthamoeba infection or from other complications (cases 1-16, 18-21, 25-29).  In one 
case, it is unknown whether the patient survived (cases 22).  Three cases were still living 
at the time of the published report, with follow-ups of one month (case 24) and 12 
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months (case 23). The third report did not give a timeframe but mentioned the patient was 
still being maintained on therapy (case 17). 
In contrast, only seven cases of disseminated Balamuthia have been reported.  
[See Appendix A, Table 2 for all disseminated balamuthiasis case references.]  The 
information concerning potential health-related predisposing factors for these cases was 
limited and varied, including a history of alcohol or drug abuse (n=3; cases 1, 2, 6), otitis 
media (n=1, case 5), a history of a farm accident resulting in a contaminated wound and 
subsequent limb amputation (n=1, case 3), and ankylosing spondylitis (n=1; case 4).  One 
case-patient had a history of coronary artery disease (case 7), but it is unclear whether 
this medical condition was significant or not given that Balamuthia organisms were 
found in the CSF and skin but nowhere else.  Unlike acanthamoebiasis, all the 
manifestations of disseminated balamuthiasis included GAE.  The majority of cases were 
GAE and cutaneous infections (n=4; cases 3, 4, 6, 7), and the rest were GAE with 
infection of another organ outside the brain (n=3; cases 1, 2, 5). 
As with disseminated acanthamoebiasis, the majority of cases of disseminated 
balamuthiasis were in adult males (n=6; cases 1-4, 6, 7).  Only one child was reported to 
have this manifestation of illness and this case was female (case 5); this same case was 
reported as being of Hispanic ethnicity and having a travel history to Mexico.  Ethnicity 
was reported in one other case (case 6, Hispanic), but the remaining 5 case-patients with 
disseminated balamuthiasis had no ethnicity reported so no pattern can be determined 
from these data.  Environmental exposure history was limited with only two reports 
providing information: both mentioned potential soil exposures (case 3, 4).  When 
timeframes could be determined, the number of days between suspected onset of 
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symptoms and death ranged from 24 to 568 days (cases 1-3, 5-7).  One case-patient 
resolved his infection and did not die, but the case report did not provide adequate 
information to determine the time period between symptom onset and resolution (case 4).  
The number of days between hospitalization and death ranged from 13 to 77 days (cases 
1-3, 5-7).  Clinical outcomes for disseminated Balamuthia disease were also poor, with 
six of the case-patients dying (cases 1-3, 5-7) and one reported survivor (case 4).  This 
patient was followed for more than five years and seemed to have recovered from his 
infection. 
Granulomatous amebic encephalitis (GAE) 
There are 21 published reports of granulomatous amebic encephalitis caused by 
Acanthamoeba spp. from 1955 to 2009.  [See Appendix A, Table 3 for all Acanthamoeba 
GAE case references.]  Similar to the disseminated form of acanthamoebiasis, the most 
common predisposing condition among infected patients was HIV/AIDS (n=4, cases 10, 
11, 14, 20), and an equal number of patients with GAE had a history of substance and 
alcohol abuse (n=4; cases 2, 3, 15, 21).  Other potential predisposing health conditions 
included: cancer (n=2) with long-term immunosuppression (case 5) and with a stem cell 
transplant (case 16); organ transplantation (n=2) with immunosuppressive therapy (cases 
17) and with diabetes (case 19); lupus (n=2; case 18), where one case-patient was also 
dependent on drugs and alcohol and counted above as having history of substance abuse 
(case 21); mixed connective tissue disorder (n=1; case 9); and pneumonitis (n=1, case 6).  
One case-patient (case 4) had a stroke, but it is unknown if this may be a predisposing 
condition.  Of the 21 reports, five had either unknown or unpublished health conditions 
(cases 1, 7, 8, 12, 13) that may have made them more susceptible to infection. 
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The majority of cases of Acanthamoeba GAE were adult males (n=13; cases 2-5, 
10-15, 17, 19, 20).  Only three cases were in children under the age of 18, and all of them 
were female (cases 1, 7, 8).  There were five adult females with Acanthamoeba GAE 
(cases 6, 9, 16, 18, 21).  No case reports noted patients of Hispanic ethnicity.  Two 
reports noted that case-patients had water exposures; one case-patient was exposed to 
water that had accumulated in a basement (case 3), but the source of the water was not 
specified, and the other case-patient frequently used swimming pools for therapy after a 
cerebrovascular accident (case 4).  A third case-patient, a male, had multiple exposures, 
including a potential occupational exposure (general contractor) and exposures to water 
and soil.  He played volleyball on sand courts and also gardened as a hobby.  He also 
enjoyed fishing and was on a trip approximately one month prior to his illness onset, 
although he denied direct water contact (case 19).  The remaining 18 case reports did not 
comment on potential environmental exposures.  When timeframes could be determined, 
the number of days between suspected onset of symptoms and death ranged from 8 to 
252 days (cases 1, 5, 6, 9, 10, 11, 14-21).  Seven did not have adequate information on 
the symptom onset/death timeframe (cases 2-4, 7, 8, 12, 13).  The number of days 
between hospitalization and death ranged anywhere from 4 to 63 days (cases 1, 2, 3, 5, 9, 
10, 11, 14, 16, 17, 21).  Ten cases did not have adequate information on the 
hospitalization/death timeframe (cases 4, 6-8, 12, 13, 15, 19, 20).  Among cases where 
the clinical outcome was known, fatality was 100% (cases 1-7, 9-11, 14-21).  Three cases 
had unknown outcomes (cases 8, 12, 13). 
Thirty-nine cases of Balamuthia GAE in the United States have been published in 
case reports or cited in summary compilations.  [See Appendix A, Table 4 for all 
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Balamuthia GAE case references.]  Eleven case reports did not include information that 
lent evidence of predisposing health factors, nor was the patient’s status stated as being 
healthy (cases 3, 4, 6, 9, 23-25, 30, 31, 35, 36).  Nine cases were reported as being 
previously healthy before becoming ill (cases 7, 10, 12, 13, 15, 20, 21, 27, 32).  In 
instances where predisposing health factors were known, nine cases had otitis, 
pharyngitis, or some other type of respiratory illness (cases 2, 5, 11, 14, 18, 19, 22, 33, 
37).  Five cases had a history of alcohol or drug abuse (cases 5 [also had TB as noted 
above], 8, 17, 26, 29,).  Other predisposing health factors included: organ transplantation 
and immunosuppressive therapy (cases 34, 38, 39), HIV (case 16), prolonged steroid use 
(case 28), and diabetes (case 1). 
Unlike Acanthamoeba GAE, the majority of cases of Balamuthia GAE were in 
males younger than the age of 18 years (n= 14; cases 2, 3, 9, 13-15, 18, 23, 24, 28, 30, 
32, 36, 37) followed by adult males (n= 11; cases 5, 6, 8, 17, 25, 26, 29, 31, 33, 35, 39).  
There were eight case reports on females under age 18 (cases 4, 7, 10-12, 20-22) and five 
adult women (cases 1, 16, 19, 27, 38).  One case report did not include any age or gender 
information (case 34).  Fourteen of the cases (cases 7, 10, 15, 17, 21-25, 28-31, 36) were 
reported to be of Hispanic ethnicity; the rest of the case reports did not include 
information on ethnicity.  Environmental exposure to soil was cited in six cases (cases 7, 
25, 27, 30, 33, 35).  Two patients cited gardening as a hobby (cases 27, 35), two had an 
occupational exposure to soil (case 25, 33), one cited motorcycling in the desert as a 
hobby (case 30), and one visited a farm (case 7).  One case-patient had a history of 
frequent outdoor play in soil as well as exposure to an untreated well-water source for 
recreation and drinking (case 37).  Three additional cases cited water exposure, one to a 
 
14 
 
freshwater pond (case 20), one to well water (case 1), and one to a lake (the latter may 
have also had soil exposure as the child of a migrant farmer, case 9).  When timeframes 
were able to be determined, the number of days between suspected onset of symptoms 
and death ranged from 8 to 240 days (cases 1-5, 7, 10, 12-15, 17-19, 22, 24, 25, 33, 37, 
38).  Five cases resolved their infections and did not die (cases 21, 27, 31, 32, 39) and 
fourteen did not have adequate information on the symptom onset/death timeframe (cases 
6, 8, 9, 11, 16, 20, 23, 26, 28, 29, 30, 34, 35, 36).  The number of days between 
hospitalization and death ranged anywhere from 3 to 120 days (cases 1, 2, 9, 11, 16, 20, 
26, 28-30, 35, 36).  Twenty-two cases did not have adequate information on the 
hospitalization/death timeframe (cases 3-8, 10, 12-15, 17-19, 22-25, 33, 34, 37, 38).  
Survival for those with Balamuthia GAE was slightly better for those with GAE caused 
by Acanthamoeba spp.  Four patients are reported to have survived (case 21, 27, 31, 39) 
and the other 35 died (cases 1-20, 22-26, 28-30, 32-38). 
Cutaneous acanthamoebiasis 
 Twelve cases of cutaneous acathamoebiasis occurring in the United States have 
been reported in the literature and all cases were among immunocompromised adults.  
[See Appendix A, Table 5 for all cutaneous acanthamoebiasis case references.]  The main 
predisposing medical condition was HIV/AIDS (n=10; cases 1-4, 6-11).  The only other 
condition cited in the literature was immunosuppression due to organ transplantation 
(n=2; cases 5, 12).  Nine of the case-patients were males (cases 1-7, 9, 10) and three were 
females (cases 8, 11, 12).  Two case reports noted that the patients were of Hispanic 
ethnicity (cases 2, 8), but ethnicities were not reported for the other 10 case-patients.  No 
soil exposures were cited in the case reports, although two reports noted cases had 
 
15 
 
freshwater exposure before skin lesions appeared (cases 6, 7).  One case was noted to 
have a local creek nearby that was used as a domestic drinking water source (case 12).  
No potential environmental exposures were cited for the remaining nine case-patients.  
When timeframes could be determined, the number of days between suspected onset of 
symptoms and death ranged from 22 to 450 days (cases 1-4, 6, 8-11).  Two cases 
resolved their infections and did not die (cases 5, 12) but the symptom onset/death 
timeframes could not be determined and one fatal case did not have adequate information 
on the symptom onset/death timeframe (case 7).  The only report of number of days 
hospitalized was in a survivor who was hospitalized for approximately 150 days (case 
12).  The remaining cases did not have adequate information on the hospitalization/death 
or hospitalization/discharge timeframes (cases 1-11).  There were three reported 
survivors of cutaneous Acanthamoeba (cases 5, 11, 12) and the other nine cases resulted 
in death (cases 1-4, 6-11). 
Acanthamoeba rhinosinusitis 
Two cases of Acanthamoeba rhinosinusitis have been reported in the literature.  
[See Appendix A, Table 6 for all Acanthamoeba rhinosinusitis case references.] Both 
patients were immunocompromised adults, one male (case 1) and one female (case 2).  
The male had HIV and recurrent sinus problems and the female had undergone a bilateral 
lung transplantation due to a progressive lung disease.  Both of these patients are reported 
to have resolved their infections at 4 (case 1) and 3 (case 2) weeks respectively, but no 
further follow-up was mentioned in either article. 
Acanthamoeba osteomyelitis 
A lone case of Acanthamoeba osteomyelitis was reported in 1981 in a 32-year-old 
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pre-diabetic woman.  [See Appendix A, Table 7 for all Acanthamoeba osteomyelitis case 
references.]  She had a mass in the right mandibular area, which was removed and 
replaced with a bone graft.  A subsequent surgery was necessary in order to remove 
necrotic bone.  Inflammatory exudate from bone marrow in the necrotic bone was 
positive for Acanthamoeba.  The report does not cite any follow-up after the patient’s 
surgery for necrotic bone removal, so it is not known if  she continued to improve and 
remain ameba-free (case 1).  Three other cases of Acanthamoeba osteomyelitis have been 
reported in the literature, but all of these case patients had disseminated Acanthamoeba 
infection (see Appendix A, Table 1, cases 17, 18, 27). 
Survivors: Acanthamoeba 
 There have been nine reports of successful treatment of acanthamoebiasis: three 
disseminated (Appendix A, Table 1, cases 17, 23, 24), three cutaneous (Appendix A; 
Table 4, cases 5, 11, 12), two rhinosinusitis (Appendix A, Table 5, cases 1, 2), and one 
osteomyelitis (Appendix A, Table 6, case 1).  There have been four published cases 
where the clinical outcome was unknown due to lack of information in the reports: one 
was a disseminated disease case (Appendix A, Table 1, case 22) and three were GAE 
cases (Appendix A, Table 3, cases 8, 12, 13).  In 1998, a report was published of a 7-
year-old male with HIV who had been diagnosed with cutaneous Acanthamoeba disease 
at 5 ½ years of age (Appendix A, Table 1, case 17).  Initially this case-patient was treated 
with fluconazole without complete resolution of his skin lesions.  Several months after 
his diagnosis of cutaneous Acanthamoeba disease, he had a painful thumb and testing 
showed osteomyelitis without a definitive cause.  He was given pentamidine daily over 
the course of a month and then maintained on itraconzole with monthly treatments of 
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pentamidine.  By the time he was 6-years-old, he was diagnosed with granulomatous 
amebic osteomyelitis after presenting with a swollen elbow.  He was again given 
pentamidine daily for one month.  His cutaneous lesions and osteomyelitis recurred when 
he was close to 7 years old, despite maintenance therapy.  Daily pentamidine for one 
month was given in combination with 5-fluorocytosine (5-FC).  The child was then 
maintained on 5-FC and antiretroviral treatment and was alive at the time of publication 
but had occasional new skin lesions. 
In 1999 a report was published of a 39-year-old woman who had undergone a 
lung transplant six years earlier (Appendix A, Table 1, case 23).  She was reported to 
have presented with skin nodules, with new nodules continuing to develop over the next 
several days.  Multiple biopsies were performed before a diagnosis of Acanthamoeba was 
finally made.  Initial treatment included a combination of 5-FC and pentamidine, as well 
as topical treatment with chlorhexidine gluconate and ketoconazole cream.  Upon going 
into respiratory failure and requiring mechanical ventilation, the patient’s 
bronchoalveolar lavage (BAL) was found to be positive for Acanthamoeba.  At this point 
azithromycin was added to her drug regimen and it appears she stayed on this regimen for 
close to a month, at which time her skin lesions were improving and her BAL was 
negative.  However, she began to have side effects that resulted in several of the 
medications being discontinued.  The patient had abnormal liver function tests and a 
biopsy showed Acanthamoeba was present in this organ, so the patient was given lower 
doses of pentamidine and 5-FC was restarted.  On discharge, the patient was still being 
treated with 5-FC and clarithromycin was added.  The woman showed no evidence of 
infection 12 months after her hospital discharge.  
 
18 
 
In 2002, a 37-year-old AIDS and cancer patient was reported to have nasal 
obstruction that did not resolve with antibiotic treatment (Appendix A, Table 1, case 24).  
He subsequently developed papular lesions on his extremities.  Multiple biopsies were 
inconclusive, although Cytomeglovirus was suspected and treatment was begun; the 
patient did not respond well.  Subsequently, the nasal obstruction became worse until the 
patient needed surgery, at which point a diagnosis of Acanthamoeba was made from the 
specimens obtained during surgery.  The patient was given pentamidine and topical 
treatments of both chlorhexidine and ketoconazole.  When he had side effects due to 
pentamidine it was discontinued and 5-FC was begun; this regimen was continued for a 
month with successful resolution of his disease.  At the time of the report, the patient was 
still taking itraconazole but there was no evidence of recurrence.  The report does not 
mention when treatment with this drug was begun. 
 Three cases of cutaneous acathamoebiasis were reported to have survived.  In 
1992, a 31-year-old man who had undergone a kidney transplant presented with skin 
nodules (Appendix A, Table 5, case 5).  Upon diagnosis of Acathamoeba via positive 
skin biopsies, he was given intravenous (IV) pentamidine and topical treatment with 
chlorhexidine and ketoconzaole.  He was treated with pentamidine for 4 weeks, although 
the dosage had to be reduced due to an elevated creatinine level. At discharge from 
hospital, his previous medications were discontinued and he was then treated with oral 
itraconazole.  He continued to take this medicine at a reduced dosage for at least two 
years after his diagnosis without recurrence of infection. 
In 2004, a 51-year-old woman with AIDS presented with skin papules, 
photophobia, and headache (Appendix A, Table 5, case 11).  Based on a skin biopsy, she 
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was diagnosed with cutaneous Acanthamoeba disease and underwent a CT scan and 
lumbar puncture, which were subsequently negative for evidence of central nervous 
system involvement.  Her treatment regimen included pentamidine and 5-FC, but new 
skin nodules continued to appear so sulfadiazine and highly active antiretroviral 
treatment (HAART) were added.  After 14 days of pentamidine once a day, penatmidine 
was discontinued and the patient was continued on maintenance therapy of 5-FC, 
sulfadiazine, and HAART.  The patient was still free of CNS involvement 3 months after 
release from the hospital with slow improvement of her skin lesions, possibly due to 
inconsistent compliance with her treatment. 
Also in 2004, a 52-year-old woman who had a lung transplant three years earlier 
and remained on immunosuppressive therapy presented with nodules on her trunk and 
lower extremities (Appendix A, Table 5, case 12).  She was diagnosed with cutaneous 
Acanthamoeba disease and unsuccessfully treated with itraconazole and metronidazole 
for two weeks.  CDC and an infectious disease specialist were consulted and the woman 
was started on IV amphotericin B lipid complex and voriconazole.  She was discharged 
on the same medications delivered through an outpatient service.  Her treatment with 
these two drugs lasted 10 weeks before the dosage and frequency were changed and IV 
voriconzole was switched to oral voriconazole.  After her discharge she was maintained 
on oral voriconazole for 5 months with resolution of her skin lesions and no recurrence. 
 Two cases of Acanthamoeba rhinosinusitis were reported to have survived their 
infections.  A 45-year-old man with HIV had sinus difficulties over the course of a year 
which necessitated multiple sinus surgeries before he was finally diagnosed with 
Acanthamoeba rhinosinusitis (Appendix A, Table 6, case 1).  He had a subtotal 
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septectomy, used gentamycin nasal rinses for 4 weeks and was maintained on oral 
itraconazole.  No timeframe was given for the maintenance therapy, nor was the time 
frame between the resolution of the infection and the publication of the paper given.  In 
2005, a 49-year-old woman who had undergone a lung transplant was reported to have 
survived Acanthamoeba rhinosinusitis (Appendix A, Table 6, case 2).  Seven months 
after transplantation she had sinus difficulties and after diagnosis was treated with 
amphotericin, voriconazole, and caspofungin.  Three weeks after treatment began she 
underwent a sinus debridement, but no Acanthamoeba were seen in specimens from this 
debridement: she remained Acanthamoeba free in the month following which is as long 
as the report states the patient was followed.  
The only other published report of an Acanthamoeba survivor was in 1981 
(Appendix A, Table 7, case 1).  A 32-year-old female was diagnosed with amebic 
osteomyelitis after a sequestrum of necrotic bone was removed from her jaw.  The patient 
does not appear to have been treated with drugs that were specific to resolving 
Acanthamoeba infections.  She was given IV penicillin, used betadine mouthwash after 
surgery, and was discharged.  The authors do not discuss long-term follow up, but as she 
was reported as still alive at the time of the published report she is counted among the 
survivors in this review.  As with many of these cases where patients were reported to 
have survived, it is difficult to determine if there were later recurrences or if patients truly 
resolved their infections and never relapsed. 
Survivors: Balamuthia 
There have been six reports of successful treatment of balamuthiasis, one with 
disseminated disease (Appendix A, Table 2, case 4) and five with Balamuthia GAE 
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(Appendix A, Table 4, cases 21, 27, 31, 32, 39).  A 64-year-old man who previously had 
a skin lesion that was biopsied with pending results presented with neurological 
difficulties (Appendix A, Table 2, case 4).  Lesions were seen in the parietal area of his 
brain on both a CT scan and a MRI.  He subsequently underwent a brain biopsy and was 
released 10 days later.  He was then re-hospitalized and received a diagnosis of B. 
mandrillaris disseminated disease as Balamuthia organisms were identified in both the 
brain tissue and the skin biopsy.  He was treated with 5-FC, fluconazole, IV pentamidine, 
sulfadiazine, and azithromycin (which was later switched to clarithromycin).  The patient 
was ventilated and in intensive care for seven weeks.  He was discharged to a 
rehabilitation unit and fluconazole was discontinued.  Following a relapse, fluconazole 
was added again and he was maintained on fluconazole and sulfadiazine over the course 
of five years.  The patient did recover enough to be able to walk, perform activities of 
daily living and communicate well. 
There have been five reports of survivors who were diagnosed with Balamuthia 
GAE.  Three of the case-patients were reported as previously healthy (Appendix A, Table 
4, cases 21, 27, 32) and one had an unknown health status (Appendix A, Table 4, case 
31).  A report published in 2003 discusses a 5-year-old girl who, 48 days after initial 
presentation, was diagnosed with Balamuthia GAE (Appendix A, Table 4, case 21).  The 
patient underwent several combinations of treatment.  Initially she was treated with 
ketoconazole and metronidazole for 34 days.  These medications were then discontinued 
and she was placed on clarithromycin and flucytosine for 14 days.  Her treatment was 
subsequently changed again and included azithromycin, fluconazole, pentamidine, and 
thioridazine.  Over the course of the next two-and-a-half years, her treatment varied, 
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primarily because of discontinuation of medications due to side effects and initiation of 
medicines due to seizures.  More than two-and-a-half years after her first hospital 
admission she was still maintained on clarithromycin and fluconazole. 
In 2004, a report was published of a 72-year-old woman who underwent a brain 
biopsy that was positive for Balamuthia (Appendix A, Table 4, case 27).  The biopsy was 
excisional, and upon diagnosis, the patient was treated with pentamidine (IV), 
sulfadiazine, fluconazole, and clarithromycin.  The patient remained asymptomatic, but it 
is unknown how much time elapsed between the case and the published report as well as 
how long she was maintained on therapy.  In 2007 a Balamuthia GAE survivor was 
reported (Appendix A, Table 4, case 31).  The report only stated that the patient was 
living at the time of his last report to a physician, but he was lost to follow-up. 
In 2010, a report of a 2-year-old boy with GAE was published (Appendix A, 
Table 4, case 32).  He was initially treated for tuberculosis but underwent a biopsy and 
was given a diagnosis of Balamuthia.  He was treated with pentamidine, fluconazole, 
flucytosine, sulfadiazine, clarithromycin, and thioridazine.  The boy was placed on a 
ventilator and required a ventriculoperitoneal shunt.  He was maintained on a ventilator 
for almost two months and then transferred to a rehabiliation unit.  Over the course of at 
least 22 months, the case-patient was given clarithromycin, sulfadiazine, flucytosine, and 
fluconazole without evidence of an active infection.  After time in the rehabilitation unit, 
the boy was able to follow simple commands, had improved postural stability, and was 
attempting to speak.  MRIs show that the lesions decreased in size and number. 
The most recent report of a Balamuthia GAE survivor was published in 2010 
(Appendix A, Table 4, case 39).  A kidney transplant recipient who acquired his infection 
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through organ transplantation from an infected donor survived the infection, although he 
spent two months in a coma.  He slowly regained cognitive and motor functions and 
entered a rehabilitation unit.  He had residual neurologic effects such as right arm 
paralysis and bilateral leg weakness.  He also had intermittent vision loss.  No treatment 
regimen was included in the publication. 
Ethnicity 
 In 2004, a letter to the editor of Emerging Infectious Diseases was published, 
suggesting that Hispanic ethnicity may be a risk factor for Balamuthia GAE.20  The 
primary authors of this letter were involved with the California Encephalitis Project 
(CEP), which was begun in 1998 with the purpose of assisting clinicians in the State with 
cases of encephalitis by offering enhanced diagnostic testing for infectious agents.  The 
CEP collects serum and other samples from patients in California that have presented 
with encephalitis, and a subset of these samples were pulled for Balamuthia screening.  
The criteria for screening included: case history that had clinical or laboratory 
information suggestive of Balamuthia GAE and either an outdoor occupational exposure 
or other outdoor recreational activity that might have lead to exposure to soil.  Of 215 
samples tested, three were positive for Balamuthia.  Four additional samples, not a part of 
the CEP, were also tested and were found to be positive.  All seven cases were healthy 
Hispanic Americans who died of GAE.  The CEP contacted CDC to obtain information 
about their records of Balamuthia cases, and it was determined that based on either case 
report identification of ethnicity or a traditional Hispanic last name, about 50%, or 25, of 
the U.S. case patients with known or suspected ethnicity were Hispanic Americans.  No 
information was given on the number of cases with truly unknown ethnicities, just that 
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there were approximately 50 U.S. cases at the time of publication.  This same letter also 
stated that 36% of Balamuthia GAE cases occurred in Latin American countries.20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER III: METHODS AND PROCEDURES 
CDC’s Free-Living Ameba (FLA) Laboratory collects information on cases of 
suspected Balamuthia and non-keratitis Acanthamoeba diseases as part of their contact 
with physicians and laboratorians who are seeking assistance with diagnosis.  The head of 
the FLA Laboratory, Dr. Govinda Visvesvara, has been working with free-living amebae 
since 1964 and has been with the FLA Laboratory since 1974.  He was the first scientist 
to isolate and subsequently name Balamuthia mandrillaris and is considered one of the 
world’s FLA experts, with more than 250 publications on the subject.  The FLA 
Laboratory is one of the only research laboratories in the United States performing 
reference diagnostic testing for free-living amebae, and the lab handles specimens tested 
through various methods such as staining of histopathologic slides, culture, and 
polymerase chain reaction (PCR).  The FLA Laboratory is one of only two known labs 
currently performing an antibody test (indirect immunofluorescence or IIF) for the free-
living amebae; the other laboratory is at the California Department of Health Services, 
which runs the California Encephalitis Project (CEP).  These two labs have historically 
shared data.  Therefore, the FLA Laboratory holds records for most of the non-
Acanthamoeba keratitis and Balamuthia mandrillaris FLA cases diagnosed in the United 
States.  It is for this reason that a review of FLA laboratory records supplemented with a 
review of the published literature should capture the majority of FLA cases diagnosed in 
the United States, even though diseases associated with the free-living amebae are not 
nationally notifiable. 
Data for this study were abstracted onto case report forms from CDC laboratory 
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and clinical consultation files for positive cases of Balamuthia and non-keratitis 
Acanthamoeba that occurred in the United States.  See Appendix B for a copy of the case 
report form.  Data in the files ranged greatly in content from laboratory specimen 
submission forms with little information about the patient’s clinical course to copies of 
extensive medical records and autopsies. 
A literature review was also performed to collect all published cases and media 
reports of Balamuthia and non-keratitis Acanthamoeba disease occurring in the U.S.  The 
published cases were then compared to the CDC-diagnosed cases to determine which 
ones referred to the same patients.  This was done in three ways: matching similar patient 
clinical and laboratory data, matching authors with contact clinicians or laboratorians, 
and consultating with Dr. Govinda Visvesvara, the aforementioned head of the FLA 
Laboratory.  Information from published case reports took precedence over CDC records 
when there was conflicting data, unless the publication conflicted with a final autopsy 
report in CDC files.  CDC records took precedence over any information found in the 
general media.  In instances where there was information on length of time but not 
specific dates for illness onset, hospitalization, and/or time from illness onset to death, 
dummy dates were entered for the purpose of calculating durations. 
In instances where published cases could not be matched with CDC cases, the 
diagnostic methods for the published cases were reviewed.  Cases tested by the following 
agencies/individuals were considered to be reputable cases based on their known 
diagnostic methods: the California Department of Health Services; Dr. Eddy Willaert, 
Institute of Tropical Medicine in Antwerp, Belgium; Dr. Julio Martinez, University of 
Pittsburgh; Dr. Bruce Torian, Idaho; Dr. Gregory Booten, Ohio State University.  If it 
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was not apparent that a published case was in CDC records, or if one of the laboratories 
above was not cited, individual cases were discussed with Dr. Visvesvara to determine if 
he was familiar with the case.  Diagnostic and clinical features of the published case were 
reviewed to determine if the case likely fit a diagnosis of acanthamoebiasis or 
balamuthiasis. 
Each case-patient identified from these records and/or the literature review was 
assigned a unique identifier consisting of a prefix of AC for Acanthamoeba or BA for 
Balamuthia, followed by a two digit number representing the calendar year in which the 
case first presented with symptoms (when known) or was either first reported to CDC or 
published in the literature.  A case number in sequential order from 001 to infinity was 
designated as the last three digits of the unique identifier.  Case information was then 
entered into a limited-user database that serves as a resource for CDC clinical 
consultation and surveillance. 
The database has 976 variables and contains both quantitative and qualitative 
data.  A major issue with the database is that many of the variables are set up as 
true/false, complicating the calculation of denominators for certain areas of data.  The 
database allows exportation of files in Excel format and splits the database information 
into eight separate files when exporting: demographics, exposure history, medical 
history, current illness, laboratory tests, histopathology, diagnostic imaging, and 
diagnostic and treatment outcomes.  For the purposes of this study, the information was 
stripped of identifiers prior to analysis.  The data were then analyzed using SPSS. 
Exported data were split into separate files for Acanthamoeba and Balamuthia.  
Each of the eight database files for each organism were imported into SPSS, labeled and 
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assigned type, values, and measures.  All eight files were also combined for each 
organism for instances where information in the separate databases needed to be 
examined together.  Data were first explored by examination of frequencies, ranges and 
means, and cross tabulations.  Research question 1 was answered using these methods, 
and frequencies, ranges, and means were used for research question 4.  For research 
question 2, frequencies were also used, but because acanthamoebiasis has so many 
manifestations, it was useful to explore the data by disease manifestation.  Therefore, 
case summaries were run using final diagnosis as the grouping variable and presenting 
symptoms in the variables column.  Research question 3 was also examined using case 
summaries with the survived variable as the grouping variable and treatment drugs in the 
variables column.  Medications given to the survivors were visualized using Excel 
spreadsheets to determine commonalities in the drugs used and duration.  Although the 
methods used above answered the research questions, I also further analyzed some of the 
demographic, exposure history, previous medical history, and outcomes data to try to 
glean further information about these diseases and produced epidemologic curves for all 
reported cases of acanthamoebiasis and balamuthiasis in the United States through 2009. 
 
 
 
 
 
 
 
 
 
CHAPTER IV: RESULTS 
A total of 114 cases of acanthamoebiasis was analyzed; 65 (57%) of these cases 
had some information about them published in the literature.  Similarly, 70 cases of 
balamuthiasis were analyzed; 46 (66%) of these cases had some information about them 
published in the literature.  Cases of acanthamoebiasis occurred between 1955 and 2009 
(Figure 1); cases of balamuthiasis occurred between 1974 and 2009 (Figure 2).  See 
Appendix C for larger versions of these figures. 
Figure 1: Epidemic Curve for Cases of Non-Keratitis Acanthamoeba spp.—United 
States, 1955-2009 
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Figure 2: Epidemic Curve for Cases of Balamuthia mandrillaris—United States, 
1974-2009 
 
Demograhics: Research Question 1 
Little information was available about the race and ethnicity of Acanthamoeba 
cases.  Sixty-two percent of the race data were missing (n=43/114).  Among the 43 case 
patients who had data available, the racial breakdown was: 63% white (n=27/43), 35% 
African American (n=15/43), and 2% American Indian (n=1/43). Ninety percent of the 
data were missing for the ethnicity variable (n=11/114), but among the known cases 82% 
(n=9/11) were Hispanic and 18% (n=2/11) were non-Hispanic.  Five out of the nine 
known Hispanics were treated in the state of California.  Immigration data were also 
limited; 93% of the data were missing (n=8/114), but when known 75% had immigrated 
to the United States (n=6/8) and 25% were natural U.S. residents (n=2/8).  There was no 
particular country of emigration in common among those six cases who had immigrated.  
Four percent of cases were missing data for the age variable (n=110/114).  Ages of cases 
ranged from a minimum of 8 months old to a maximum of 79 years old, with a mean of 
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38.8 years of age; 7% (n=8/110) were children younger than 18 years of age, 87% 
(n=96/110) were adults 18-64 years of age, and 6% (n=6/110) were 65 years of age or 
older.  Males were 73% of cases (n=82/112) and females were 27% (n=30/112); two 
cases had missing information.  See Figure 3 for an epidemic curve by age of 
Acanthamoeba spp.  [Appendix C has a larger version of this figure.]  Also see Figure 4 
for the geographic distribution of Acanthamoeba spp. cases by state of treatment. 
Figure 3: Epidemic Curve by Age for Cases of Acanthamoeba spp.—United States, 
1955-2009 
Figure 4: Geographic Distribution of Non-Keratitis Acanthamoeba spp. Cases by 
State of Treatment 
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Limited data were available for race, ethnicity, and immigration status for 
Balamuthia cases.  Fifty-three percent of the race data were missing (n=33/70).  Among 
cases where data were available, the racial breakdown was: 58% white (n=19/33), 36% 
African American (n=12/33), and 6% Asian/Pacific Islander (n=2/33). Fifty-nine percent 
of the data were missing for ethnicity (n=29/70), but among the known cases 76% were 
Hispanic (n=22/29) and 24% were non-Hispanic (n=7/29).  Twelve of the 22 known 
Hispanic case-patients were treated in the state of California.  The immigration variable 
had 84% of the data missing (n=11/70); 36% of case-patients with known immigrantion 
status immigrated to the U.S. (n=4/11) and 64% were natural residents of the U.S. 
(n=7/11).  Immigrants most commonly came from Mexico (75%, n=3/4).  Two cases 
were missing data for the age variable, with ages ranging from a minimum of 4 months to 
a maximum of 89 years of age, and a mean age of 30.4 years; 43% (n=29/68) were 
children younger than 18 years of age, 47% (n=32/68) were adults 18-64 years of age, 
and 10% (n=7/68) were 65 years of age or older.  Males were 65% of cases (n=45/69) 
and females were 35% (n=24/69); only one case was missing gender information.  See 
Figure 5 for an epidemic curve by age of Acanthamoeba spp.  [Appendix C has a larger 
version of this figure.]  Also see Figure 4 for the geographic distribution of Balamuthia 
mandrillaris cases by state of treatment. 
Figure 5: Epidemic Curve by Age for Cases of Balamuthia mandrillaris—United 
States, 1974-2009 
 
 
33 
 
 
Figure 6: Geographic Distribution of Balamuthia mandrillaris Cases by State of 
Treatment 
 
 
Table 1: Summary of Demographic Data for Non-Keratitis Acanthamoeba spp. and 
Balamuthia mandrillaris Cases 
Acanthamoeba (N=114) Balamuthia (N=70) Variable 
Data Missing Data Missing
White 63% (27/43) 58% (19/33) 
African American 35% (15/43) 36% (12/33) 
American Indian 2% (1/43) 0% (0/33) 
Race 
Asian/Pacific Islander 0% (0/43) 
 
62% 
(71/114) 
6% (2/33) 
 
53% 
(37/70) 
Hispanic 82% (9/11) 76% (22/29) Ethnicity 
Non-Hispanic 18% (2/11) 
90% 
(103/114) 24% (7/29) 
59% 
(41/70) 
Immigrant 75% (6/8) 36% (4/11) Immigration 
Non-Immigrant 25% (6/8) 
93% 
(106/114) 64% (7/11) 
84% 
(59/70) 
Range 8 m–79 y 4 m–89 y Age 
Mean 38.8 years 
4% 
(4/114) 30.4 years 
3% 
(2/70) 
Sex Male 73% (82/112) 2% 
(2/114) 
65% (45/69) 1% 
(1/70) 
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Presenting Symptoms: Research Question 2 
Patients presented with a variety of non-descriptive symptoms for both 
Acanthamoeba and Balamuthia disease.  Fever and headache were the two most common 
symptoms shared by those with either disease.  See Tables 2 and 3 for the top ten 
symptoms patients presented with upon examination or hospitalization for illness caused 
by Acanthamoeba spp. and Balamuthia mandrillaris respectively. 
Table 2: Top Ten Presenting Symptoms of Patients Later Diagnosed With Non-
Keratitis Acanthamoeba spp. Infection (N=95/114) 
Presenting Symptom No. of Cases Reporting Symptoms 
Other General Symptoms* 39 
Fever 34 
Headache 29 
Sinus problems 18 
Other Neurologic Deficit** 17 
Lethargy/Fatigue  13 
Confusion 9 
Weight Loss 8 
Weakness 7 
Altered Mental Status 6 
Cough 6 
Nausea 6 
Vomiting 6 
*Other general symptoms include but were not limited to: chills (n=7/39), facial 
swelling/pain/tenderness (n=5/39), epitstaxis (n-=3/39), jaundice (n=2/39), night sweats 
(n=2/39), and incontinence (n=2/39).  
** Other neurologic symptoms include but are not limited to: Romberg’s sign (n=1/17), 
Babinski sign (n=1/17), Kernig’s sign (n=1/17), Brudzinki’s sign (n=1/17). 
 
Table 3: Top Ten Presenting Symptoms of Patients Later Diagnosed With 
Balamuthia mandrillaris Infection (N=63/70) 
Presenting Symptom No. of Cases Reporting Symptoms 
Fever 23 
Headache 18 
Lethargy/Fatigue 18 
Vomiting 18 
Other General Symptoms* 16 
Other Neurologic Deficit** 15 
Seizures 14 
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Weakness 13 
Other Visual Symptoms 11 
Altered Mental Status 10 
Hemiparesis 9 
Ataxia 8 
*Other general symptoms include but were not limited to: incontinence (n=3/16), neck 
pain (n=2/16), and loss of appetite (n=2/16).  
** Other neurologic symptoms include but are not limited to:Babinski sign (n=2/15, and 
unresponsiveness (n=2/15). 
 
Because both acanthamoebiasis and balamuthiasis have multiple disease 
manifestations, a further exploration was done looking at presenting symptoms by disease 
manifestation.  Symptoms were broken up into four categories: general presenting 
symptoms (17 variables), visual symptoms (4 variables), neurologic symptoms (29 
variables), and skin lesions (4 variables).  Cases that had no information for every 
variable in a category were taken out of the frequency counts and treated as unknowns.  
Remaining cases may have had more than one symptom in each of the four presenting 
symptom categories.  In the case of the skin lesions category, knowns included those 
cases who indicated they had skin lesions or did not have skins lesions.  After analysis it 
was apparent that not all of the possible variables for the symptom categories were 
selected as symptoms upon presentation.  See Tables 4-7 for breakdowns of 
Acanthamoeba cases; see table footnotes for numbers of variables not chosen in each 
category. 
Table 4: Presenting General Symptoms for Cases of Non-Keratitis Acanthamoeba 
spp. Infection by Disease Manifestation 
Disease Manifestation Presenting Symptom No. of Known Cases 
Reporting Symptoms 
Other General Symptoms 19 
Fever 12 
Sinus problems 11 
Headache 10 
Lethargy/Fatigue 5 
Disseminated 
(n=30/36)* 
Cough 4 
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Nausea 3 
Weight Loss 3 
Shortness of breath 2 
Vomiting 1 
Stiff Neck 1 
 
Fever 16 
Headache 14 
Other General Symptoms 14 
Lethargy/Fatigue 7 
Vomiting 4 
Nausea 3 
Weight Loss 3 
Diarrhea 2 
Anorexia 1 
Cough 1 
Shortness of Breath 1 
GAE (n=25/48)* 
Sinus Problems 1 
 
Fever 5 
Headache 3 
Other General Symptoms 4 
Diarrhea 2 
Weight Loss 2 
Myalgia 2 
Sinus Problems 2 
Shortness of Breath 1 
Cutaneous (n=10/23)* 
Lethargy/Fatigue 1 
 
Sinus Problems 4 
Fever 1 
Headache 1 
Rhinosinusitis (n=4/6)* 
Other General Symptoms 1 
 
Osteomyelitis (n=1/1) Other General Symptoms 1 
*Those reporting multiple general symptoms on initial presentation included: 19 GAE 
cases, 24 disseminated cases, two rhinosinusitis cases, and six cutaneous cases. 
Although it was possible to select up to 17 variables for presenting general symptoms, 
three of those variables were not selected among those cases who reported presenting 
symptoms. 
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Table 5: Presenting Visual Symptoms for Cases of Non-Keratitis Acanthamoeba spp. 
Infection by Disease Manifestation 
Disease Manifestation Presenting Symptom No. of Known Cases 
Reporting Symptoms 
Blurred Vision 2 
Diplopia 1 
Disseminated (n=3/36)* 
Other Visual Symptom 1 
 
Blurred Vision 2 
Diplopia 2 
Other Visual Symptom 2 
GAE (n=5/48)* 
Photophobia 1 
 
Cutaneous (n=2) Photophobia 2 
*Those reporting multiple visual symptoms on initial presentation included: two GAE 
cases and one disseminated case. 
 
Table 6: Presenting Neurologic Symptoms for Cases of Non-Keratitis Acanthamoeba 
spp. Infection by Disease Manifestation 
Disease Manifestation Presenting Symptom No. of Known Cases 
Reporting Symptoms 
Confusion 5 
Other Neurologic Deficit 4 
Weakness 3 
Altered Mental Status 3 
Behavioral Changes 1 
Dysphagia 1 
Hallucinations 1 
Seizures 1 
Disseminated 
(n=12/36)* 
Hemiparesis 1 
 
Other Neurologic Deficit 12 
Weakness 4 
Hemiparesis 3 
Seizures 3 
Confusion 3 
Altered Mental Status 2 
Aphasia 2 
Ataxia 2 
Numbness or Facial 
Numbness 
1 
Hyperreflexia 1 
GAE (n=22/48)* 
Nystagmus 1 
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Other Neurologic Deficit 1 Cutaneous (n=2/23) 
Altered Mental Status 1 
*Those reporting multiple neurologic symptoms included: 10 GAE cases and four 
disseminated cases. 
Although it was possible to select up to 29 variables for presenting neurologic symptoms, 
15 of those variables were not selected among those cases who reported presenting 
symptoms. 
 
Table 7: Presenting Skin Lesions for Cases of Acanthamoeba spp. Infection by 
Disease Manifestation 
Disease Manifestation Type of Skin Lesion No. of Known Cases 
Reporting Symptoms 
Other Type 16 
Ulcers 7 
Erythematous Nodules 6 
Disseminated 
(n=34/36)* 
No Skin Lesions 7 
 
Other Type 3 
Ulcers 1 
GAE (n=7/48) 
No Skin Lesions 3 
 
Other Type 9 
Erythematous Nodules 7 
Ulcers 5 
Cutaneous (n=23/23)* 
Type Not Stated 4 
 
Ulcers 1 Rhinosinusitis (n=2/6) 
No Skin Lesions 1 
*Those reporting multiple types of skin lesions on initial presentation included: four 
disseminated cases and two cutaneous cases. 
Although it was possible to select up to 4 variables for presenting skin lesions, one of 
those variables were not selected among those cases who reported presenting symptoms. 
 
 Although the manifestations of balamuthiasis appear to be limited to GAE and 
disseminated infection, which potentially have similar presenting symptoms, a 
breakdown by disease manifestation and the same four presenting symptom categories 
was done for cases of Balamuthia mandrillaris.  This allows for an examination of any 
similarities or differences in manifestations as well as a comparison to Acanthamoeba 
GAE and disseminated disease.  Balamuthia cases that had no information for any 
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variable in a category were taken out of the frequency counts and treated as unknowns.  
Remaining cases may have had more than one symptom in each of the 4 presenting 
symptom categories.  See Tables 8-11 for presenting symptoms of Balamuthia GAE and 
disseminated balamuthiasis. 
Table 8: Presenting General Symptoms for Cases of B. mandrillaris Infection by 
Disease Manifestation 
Disease Manifestation Presenting Symptom No. of Known Cases 
Reporting Symptoms 
Headache 3 
Nausea 2 
Vomiting 2 
Other General Symptoms 2 
Fever 1 
Diarrhea 1 
Weight Loss 1 
Stiff Neck 1 
Disorientation 1 
Disseminated (n=5/8)* 
Lethargy/Fatigue 1 
 
Fever 20 
Vomiting 16 
Headache 15 
Lethargy/Fatigue 15 
Other General Symptoms 14 
Nausea 5 
Anorexia 3 
Stiff neck 2 
Disorientation 2 
GAE (n=41/62)* 
Diarrhea 1 
*Those reporting multiple general symptoms on initial presentation included: 25 GAE 
cases and three disseminated cases. 
Although it was possible to select up to 17 variables for presenting general symptoms, 
four of those variables were not selected among those cases who reported presenting 
symptoms. 
 
Table 9: Presenting Visual Symptoms for Cases of B. mandrillaris Infection by 
Disease Manifestation 
Disease Manifestation Presenting Symptom No. of Known Cases 
Reporting Symptoms 
Disseminated (n=1/8) Other Visual Symptom 1 
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Other Visual Symptom 10 
Diplopia 4 
GAE (n=13/62)* 
Photophobia 1 
*Those reporting multiple visual symptoms on initial presentation included: two GAE 
cases. 
Although it was possible to select up to 4 variables for presenting visual symptoms, one 
of those variables were not selected among those cases who reported presenting 
symptoms. 
 
Table 10: Presenting Neurologic Symptoms for Cases of B. mandrillaris Infection by 
Disease Manifestation 
Disease Manifestation Presenting Symptom No. of Known Cases 
Reporting Symptoms 
Other Neurologic Deficit 3 
Hemiparesis 2 
Seizures 2 
Altered Mental Status 1 
Aphasia 1 
Confusion 1 
Hallucinations 1 
Disseminated (n=5/8)* 
Weakness 1 
 
Other Neurologic Deficit 12 
Weakness 12 
Seizures 12 
Altered Mental Status 9 
Ataxia 8 
Hemiparesis 7 
Behavioral Changes 6 
Aphasia 5 
Confusion 4 
Cranial Nerve Deficit VI 3 
Other Cranial Nerve 
deficit 
3 
Cranial Nerve Deficit VII 2 
Dysphagia 1 
Facial Numbness 1 
Hallucinations 1 
Combativeness 1 
Hyperreflexia 1 
Loss of Balance 1 
GAE (n=48/62)* 
Nystagmus 1 
Those reporting multiple neurologic symptoms on initial presentation included: 22 GAE 
cases and five disseminated cases. 
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Although it was possible to select up to 29 variables for presenting neurologic symptoms, 
10 of those variables were not selected among those cases who reported presenting 
symptoms. 
 
Table 11: Presenting Skin Lesions for Cases of B. mandrillaris Infection by Disease 
Manifestation 
Disease 
Manifestation 
Type of Skin Lesion No. of Known Cases 
Reporting Symptoms 
Other type 3 Disseminated 
(n=4/8) Ulcers 1 
 
Other type 3 GAE (n=17/62) 
No Skin Lesions 14 
Although it was possible to select up to 4 variables for presenting skin lesions, two of 
those variables were not selected among those cases who reported presenting symptoms. 
 
 In looking at a comparison of the top five presenting general symptoms for 
disseminated acanthamoebiasis and balamuthiasis (Table 12), three of the top five were 
the same.  The differences were that disseminated acanthamoebiasis cases reported sinus 
problems and lethargy/fatigue and disseminated balamuthiasis did not.  But Balamuthia 
cases experienced vomiting and nausea frequently enough to be in the top five general 
symptoms.  For presenting neurologic symptoms, the top five symptoms were similar for 
both disseminated diseases but varied in that disseminated acanthamoebiasis cases 
reported behavioral changes and dysphagia.  Disseminated acanthamoebiasis cases 
reported more visual symptoms more types of skin lesions than disseminated 
balamuthiasis cases. 
Table 12: Comparison of Top Five Presenting Symptoms for Disseminated 
Acanthamoeba and Balamuthia Disease 
General Symptoms 
Acanthamoeba (n=30/36) Balamuthia (n=5/8) 
Presenting 
symptom 
No. of Known 
Cases Reporting 
Symptoms 
Presenting 
symptom 
No. of Known 
Cases Reporting 
Symptoms 
Other General 19 Headache 3 
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Symptoms 
Fever 12 Nausea 2 
Sinus Problems 11 Vomiting 2 
Headache 10 Other General 
Symptoms 
2 
Lethargy/Fatigue 5 Fever 2 
 
Neurologic Symptoms 
Acanthamoeba (n=12/36) Balamuthia (n=5/8) 
Confusion 5 Other 
Neurologic 
Symptom 
3 
Other Neurologic 
Symptom 
4 Hemparesis 2 
Weakness 3 Seizures 2 
Altered Mental 
Status 
3 Altered Mental 
Status, Aphasia, 
Confusion, 
Hallucinations, 
Weakness 
Each symptom had 
a count of 1 
Behavioral 
Changes, 
Dysphagia, 
Hallucinations, 
Seizures, 
Hemiparesis 
Each symptom 
had a count of 1 
  
 
Visual Symptoms 
Acanthamoeba (n=3/36) Balamuthia (n=1/8) 
Blurred Vision 2 Other Visual 
Symptom 
1 
Diplopia 1   
Other Visual 
Symptom 
1   
    
Skin Lesions 
Acanthamoeba (n=34/36) Balamuthia (n=4/8) 
Other Type 16 Other Type 3 
Ulcers 7 Ulcers 1 
Erythematous 
Nodules 
6   
No Skin Lesions 7   
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In comparing the top five presenting general symptoms for Acanthamoeba and 
Balamuthia GAE (Table 13), four of the five were the same.  The only difference was 
that Acanthamoeba GAE cases reported nausea, whereas Balamuthia GAE cases reported 
vomiting.  The presenting neurologic symptoms also differed somewhat, with 3 of the 5 
being the same, but Acanthamoeba GAE cases reported hemiparesis and confusion, 
whereas Balamuthia GAE cases indicated having altered mental status and ataxia.  
Acanthamoeba GAE case-patients reported blurred vision where as Balamuthia GAE 
case-patients did not; Balamuthia GAE case-patients reported a high number of other 
visual symptoms.  Both had reports of skin lesions but they were not diagnosed as 
cutaneous disease manifestations of Acanthamoeba or Balamuthia. 
Table 13: Comparison of Top Five Presenting Symptoms for Acanthamoeba and 
Balamuthia GAE 
General Symptoms 
Acanthamoeba (n=25/48) Balamuthia (n=41/62) 
Presenting 
symptom 
No. of Known 
Cases Reporting 
Symptoms 
Presenting 
symptom 
No. of Known 
Cases Reporting 
Symptoms 
Fever 16 Fever 20 
Headache 14 Vomiting 16 
Other General 
Symptom 
14 Headache 15 
Lethargy/Fatigue 7 Lethargy/Fatigue 15 
Nausea 4 Other General 
Symptom 
14 
 
Neurologic Symptoms 
Acanthamoeba (n=22/48) Balamuthia (n=48/62) 
Other Neurologic 
Symptoms 
12 Other Neurologic 
Symptoms 
12 
Weakness 4 Weakness 12 
Hemiparesis 3 Seizures 12 
Seizures 3 Altered Mental 
Status 
9 
Confusion 3 Ataxia 8 
 
Visual Symptoms 
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Acanthamoeba (n=5/48) Balamuthia (n=13/62) 
Blurred Vision  2  Other Visual 
Symptom  
10  
Diplopia  2  Diplopia  4  
Other Visual 
Symptom  
2  Photophobia  1  
Photophobia  1    
    
Skin Lesions 
Acanthamoeba (n=5/48) Balamuthia (n=13/62) 
Other Type  3  Other Type  3  
Ulcers  1  No Skin Lesions  14  
No Skin Lesions  3    
 
Treatment: Research Question 3 
The survivors of Acanthamoeba infection were cases whose disease 
manifestations were cutaneous, rhinosinusitis or disseminated infection, typically 
involving skin and sinuses.  There has not been a reported case of Acanthamoeba GAE, 
or disseminated acanthamoebiasis with GAE involvement, that has survived.  Among the 
survivors of Acanthamoeba disease of those with known outcomes (n=9/86), there was 
no common drug used in all cases; however, five cases took itraconzole and four cases 
took pentamidine (Table 14).  Drug commonalities by Acanthamoeba disease 
manifestation are also summarized in Table 14. Non-survivors also took many of the 
same drugs.  Cases that had no information for any drug listed in the database, or that had 
unknown outcomes, were taken out of the frequency counts and treated as unknowns.  
Among Balamuthia survivors (n=6), there were also no common drugs used in all cases, 
although fluconazole and pentamidine was used in all but one instance (Table 15).  Drug 
commonalities by Balamuthia disease manifestation are also summarized in Table 15.  
Again, non-survivors also took many of the same drugs. 
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Table 14: Drugs in Common for Non-Keratitis Acanthamoeba Survivors Compared 
to Non-Survivors 
 Drug No. of Survivors 
With Known 
Treatment   
No. of non-
Survivors with 
Known Treatment  
Itraconazole* 5/9 6/47 
Pentamidine 4/9 11/47 
Ketoconazole 3/9 6/47 
Chlorhexidine topical 3/9 3/47 
Amphotericin B 2/9 14/47 
Flucytosine 2/9 6/47 
All manifestations 
Voriconazole 2/9 5/47 
 
Itraconazole 2/3 4/21 
Ketoconazole 2/3 3/21 
Pentamidine 2/3 5/21 
Disseminated 
Chlorhexidine topical 2/3 1/21 
 
GAE  No Survivors  
 
Cutaneous Itraconazole 2/3 2/7 
 Pentamidine 2/3 4/7 
 
Rhinosinusitis  No Drugs in 
Common for 
Survivors (n=2) 
 
    
Osteomyelitis  1 case  
 
Table 15: Drugs in Common for Balamuthia Survivors Compared to Non-Survivors 
 Drug No. of Survivors 
With Known 
Treatment 
No. of non-
Survivors with 
Known Treatment  
Fluconazole* 5/6 7/40 
Pentamidine* 5/6 6/40 
Clarithromycin* 4/6 1/40 
Sulfadiazine* 4/6 6/40 
Flucytosine* 4/6 4/40 
Azithromycin* 3/6 3/40 
All manifestations 
Ketaconazole 2/6 0/401 
 
Disseminated  1 case  
 
GAE Azithromycin 2/5 3/35 
 
46 
 
Clarithromycin 3/5 1/35 
Fluconazole 4/5 5/35 
Flucytosine 3/5 4/35 
Pentamidine 4/5 5/35 
Sulfadiazine 3/5 4/35 
 
See Appendix C for depictions of treatment regimens over time for survivors. 
Duration of Illness: Research Question 4 
For case-patients who were diagnosed as having Acanthamoeba sp. infection and 
who were known to have died (n=77/114), 49% (n=38/77) had missing information on 
the number of days between illness onset and death.  Of the decedents with known 
durations of illness (n=39/77), the mean duration of for illness (onset until death) was 
101.  The range was from 3 to 765 days.  For case-patients with Balamuthia infections 
who were known to have died (n=61/70), 39% (n=24/61) had missing information on the 
number of days between illness onset and death.  Of the decedants with known durations 
of illness (n=37/61) the mean duration of illness (onset until death) was 74 days, with a 
range of 8 days to 568 days.  Based on the data that was seen during the collection and 
abstraction work, it appeared that the timing of diagnosis was often quite late in the 
course of illness or post-mortem. 
Further Data Analysis 
Exposures  
 There was a substantial lack of exposure data for both Acanthamoeba and 
Balamuthia cases.  Only 6% (n=7/114) of Acanthamoeba cases had information about 
water exposured, six had exposures and one did not.  Only 4% (n=4/114) had information 
about soil exposures; all four cases reportedly had exposure.  One case reported an 
occupational exposure where the individual worked with animals.  Only 20% (n=23/114) 
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of Acanthamoeba cases had information about travel and only two out of these included 
information about their travel.  One case-patient reportedly visited Mexico and one was 
noted to have “traveled extensively,” with no further details provided. 
Only 17% (n=12/70) Balamuthia cases had information about water exposures; 
nine had exposures and three did not.  Only 20% (n=14/70) had information about soil 
exposure; 12 cases had known exposures whereas two did not.  Fifteen (21%) had 
occupational exposure information with four reporting actual occupations (three were 
farmers/ranchers or living on a farm, one was a firefighter).  Half (n=35/70) of the cases 
had information about travel history and, of those, 12 gave travel location information 
and 23 did not.  The country cited most frequently in the travel history was Mexico (7 
cases). 
Medical History 
HIV status was reported for 58% (n=66/114) of Acanthamoeba cases; a minimum 
of 52% (n=59/114) of patients who became infected with Acanthamoeba spp. had HIV.  
Patients’ AIDS status was known for 53% of cases (n=60/114); a minimum of 47% 
(n=54/114) of patients with Acanthamoeba disease had AIDS, of which 81% (n=44/54) 
had CD4 counts or another illness that indicated AIDS and 19% (n=10/54) did not. 
Past medical history data, when available, also showed a variety of respiratory 
illnesses, other immunocompromising conditions, and prescription and illegal drug use, 
all of which might have predisposed patients to infection with Acanthamoeba spp. (Table 
16).  Twelve cases had no information on past medical history. 
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Table 16: Past Medical Conditions That May Be Predisposing Factors for Non-
Keratitis Acanthamoeba spp. Infection (N=102/114) 
 No. of Cases Reporting Condition 
Respiratory Conditions  
Pneumonitis 30 
Sinusitis 14 
Other 5 
Deviated Septum 2 
TB 2 
Nasal Surgery 1 
Pharyngitis 1 
 
Immunocompromising Conditions  
HIV 59 
Organ transplant 22 
Cancer 18 
Diabetes 8 
Renal failure 7 
Alcohol misuse 5 
Lymphoproliferative disease 5 
Other autoimmune disease 4 
Systemic lupus erthematosus 3 
Other hematologic disease 3 
Cirrohosis 1 
 
Treatment/drugs  
Steriod use 17 
Immunosuppressants 16 
Eye Infections 7 
Illegal drug use 6 
Excessive antibiotic use 1 
Skin infections 1 
 
Because HIV/AIDS seemed to be so frequent among the Acanthamoeba cases, a further 
breakdown of other immunocompromising illnesses was done by HIV status.  See Table 
17. 
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Table 17: Positive Non-Keratitis Acanthamoeba Patients Reporting Another 
Immunocompromising Condition by HIV Status 
Immunocompromising 
Conditions 
No. of HIV-Positive 
Cases Reporting 
Another Condition 
(n=7/59)* 
No. of HIV-
Negative 
Cases 
Reporting 
Another 
Condition 
(n=7/7)** 
No. of HIV 
Unknown 
Cases 
Reporting 
Another 
Condition 
(n=27/48)*** 
Cancer 3 2 13 
Alcohol Misuse 2 2 1 
Other Hematologic Disease 2 0 1 
Renal failure 1 1 5 
Other Autoimmune Disease 1 1 2 
Organ Transplant 0 5 17 
Diabetes 0 2 6 
Systemic Lupus 
Erythematosus 
0 1 2 
Lymphoproliferative Disease 0 0 4 
Cirrhosis 0 0 1 
*Two HIV-positive Acanthamoeba cases had multiple immunocompromising conditions. 
**Five HIV-negative cases had multiple immunocompromising conditions. 
*** Eighteen cases had multiple immunocompromising conditions. 
Other hematologic disease included: end-stage renal disease, hemophilia, and 
myelodysplastic syndrome. 
Other autoimmune disease included: progressive transverse myelitis, graft vs. host 
disease, hemolytic anemia, and discoid lupis; hypogammaglobullnemia. 
 
Unlike Acanthamoeba spp. infection, Balamuthia cases did not typically have 
HIV.  Fifty-six percent of cases had an unknown HIV status (n=39/70).  Of the 31 cases 
with a known status, only 26% (n=8/31) were HIV positive and 74% (n=23/31) were 
negative.  Of the eight cases that had HIV, four had progressed to AIDS.  See Table 18 
for previous medical history that may predispose patients to infection with Balamuthia 
mandrillaris.  Twenty-four cases had no information on past medical conditions. 
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Table 18: Past Medical Conditions That May Be Predisposing Factors for 
Balamuthia mandrillas Infection (N=46/70) 
 No. of Cases Reporting Condition  
Respiratory Conditions  
Otitis 6 
Pharyngitis 3 
Pneumonitis 3 
TB 3 
Other 2 
Deviated Septum 1 
Nasal surgery 1 
Sinusitis 1 
 
Immunocompromising Conditions  
Alcohol misuse 9 
HIV 8 
Diabetes 4 
Organ transplant 3 
Renal failure 3 
Other hematologic disease 2 
Cirrohosis 1 
 
Treatment/drugs  
Illegal drug use 14 
Skin infections 3 
Steriod use 3 
Initial and Final Diagnoses and Outcomes 
 Seventy-eight percent of Acanthamoeba cases had missing data for admitting 
diagnosis (n=89/114).  Rarely, 8% of the time, were cases diagnosed with meningitis 
(n=1/25) or meningoencephalitis (1/25): such cases were typically diagnosed as other 
illness (92%, n=23/25) such as toxoplasmosis (n=3/23), toxoplasmosis vs. or with 
lymphoma (n=3/23), or vasculitis (n=3/23).  The remaining initial diagnoses (n=14/23) 
were varied.  Final diagnosis of Acanthamoeba cases are shown below in Table 19. 
Table 19: Final Diagnosis of Cases of Non-Keratitis Acanthamoeba spp. Infection 
 No. of Cases  Percent 
Acanthamoeba GAE 48 42% 
Disseminated acanthamoebiasis 36 32% 
Acanthamoeba rhinosinusitis 6 5% 
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Cutaneous acanthamoebiasis 23 20% 
Other: Acanthamoeba 
osteomyelitis 
1 1% 
Total 114 100% 
 
Forty percent of Balamuthia cases had missing data for admitting diagnosis (n=28/70).  
As with Acanthamoeba infection, Balamuthia cases were rarely (26%, n=12/42) 
diagnosed with encephalitis (n=3/12), meningitis (n=6/12), or meningoencephalitis 
(n=3/12) on initial presentation, and more commonly diagnosed with other illnesses 
(74%, n=30/42) such as cysticercosis/neurocysticercosis (n=3/30), toxoplasmosis 
(n=3/30), stroke (n=2/30), neoplasia (n=3/30), or acute disseminated encephalomyelitis 
(ADEM) (n=2/30).  The remaining initial diagnoses (n=25/30) were varied.  Final 
diagnosis of Balamuthia cases are shown below in Table 20. 
Table 20: Final Diagnosis of Cases of Balamuthia mandrillaris Infection 
 No. of Cases  Percent 
Balamuthia GAE 62 89% 
Disseminated balamuthiasis 8 11% 
Total 70 100% 
 Outcomes for both Acanthamoeba and Balamuthia infections were poor.  Twenty-
eight cases of Acanthamoeba had unknown outcomes (25%, n=114).  Of the cases with 
known outcomes, 10% of case-patients survived (n=9/86) and 90% died (n=77/86).  
Prognosis for those with Balamuthia infection was similar.  Three cases had unknown 
outcomes (4%, n=70).  Of the cases with known outcomes, 9% survived (n=6/67) 
survived and 91% died (n=61/67). 
 
 
 
 
 CHAPTER V: DISCUSSION AND CONCLUSION 
In examining the demographics of both Acanthamoeba and Balamuthia cases, the 
fact that the disease manifestations are far more common in men than women was one of 
the only conclusions that could be drawn from the data.  The completeness of answers for 
this question was almost 100% in both Acanthamoeba and Balamuthia datasets.  
Similarly, the data on age was more than 96% complete for both groups.  The vast 
majority (87%) of Acanthamoeba cases occurred in adults aged 18–64 years with a mean 
age of 38.8 years.  However, the pattern for Balamuthia cases tended towards younger 
persons; while most (47%) were still adults 18–64 years of age, a large proportion of 
Balamuthia cases (43%) occurred in children younger than 18 years of age. 
The scarcity of ethnicity data makes it difficult to interpret an epidemiologic 
pattern of this variable.  More than 90% of the ethnicity data for Acanthamoeba cases 
was missing.  While 82% (n=9/11) of patients with known ethnicity were Hispanic, a 
denominator of 11 is insufficient to draw conclusions.  For Balamuthia cases, 59% of the 
ethnicity data was unknown.  As with Acanthamoeba case-patients, while Hispanics did 
make up the majority, 76% (n=22/29), when the ethnicity of the Balamuthia case-patients 
was known, a denominator of 29 may not be enough to draw conclusions from.  Schuster, 
Glaser, Honarmand, Maguire, and Visvesvara (2004) proposed that Hispanics may be at 
increased risk for Balamuthia mandrillaris infection based on the results of seven 
positive tests, all in Hispanic patients, conducted by the California Encephalitis Project 
(CEP) and because 8 of 11 cases in the State occurred in Hispanic Americans.20  The 
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authors also searched CDC records and state that “approximately 50% of the 50 North 
American patients” were Hispanic; this number is potentially biased as it is based on the 
assumption that certain surnames were ethnically Hispanic.  Also, because the California 
State Health Department has the CEP, data from that state may over-represent Hispanics 
because there are a high number of persons of that ethnicity in the state (37% based on 
U.S. Census estimates in 2009).29 
However, some suggestion of an ethnicity bias is present in the Balamuthia data. 
This thesis also examined case records at CDC and in the published literature.  In looking 
at the national proportion of Hispanic ethnicity in 1999, the median year of the 
Balamuthia dataset, it was11.5%.30  Even though the ethnicity was unknown for 41 
Balamuthia case-patients, 22 (31%) of the total Balamuthia cases (n=70) were of known 
Hispanic ethnicity, which is already greater than the population proportion.  And while 
the suggestion that balamuthiasis might be more common in Hispanics versus non-
Hispanics may be true, the cause of this possible association is unknown and might 
reflect a number of factors, possibly including different exposure patterns. 
In looking at the geographic distribution of cases, there is no apparent pattern by 
state of treatment, with cases being treated in all regions of the continental United States.  
For both Acathamoeba and Balamuthia, those states reporting more cases tended to be 
the states with larger State health departments.  Although exposure patterns might be 
different in some states, it’s worth considering that the large number of cases reported in 
California might be due to its ongoing CEP.  Similarly the large number of cases from 
Texas might be because of its proximity to and awareness of the CEP’s work.  Because 
the CEP conducts active surveillance on cases of encephalitis, it may be that the numbers 
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of free-living ameba cases from California and Texas indicate that cases are more 
frequent than supposed and are being diagnosed because the cause of encephalitis is 
being closely looked at. 
 Presenting symptom information is not encouraging in terms of gaining a better 
understanding of how to more rapidly suspect and thereby diagnosis and treat free-living 
amebae infection.  Much of the presenting symptom information was missing from cases 
diagnosed with Acanthamoeba GAE, ranging from 48% missing on general symptoms to 
90% missing visual symptoms.  Gaps in visual symptom and neurologic symptom data 
were also apparent for disseminated acanthamoebiasis cases and in each symptom 
category for cutaneous cases, with the exception of presenting skin lesions.  Even among 
the cutaneous cases, the type of lesion seen on presentation was highly variable and not 
pathognomonic.  While both Acanthamoeba GAE and disseminated acanthamoebiasis 
had fever and headache as the predominant general symptoms and other neurologic 
deficits and weakness were typical neurologic symptoms, these symptoms and signs are 
rather vague symptoms and can indicate many types of illness.  It may be that there are 
specific neurologic deficits that could stand out if the data were more complete. 
In contrast, cases diagnosed with Balamuthia GAE or disseminated balamuthiasis 
had better completion of data for both presenting general symptoms (34% missing) and 
neurologic symptoms (23% missing).  Similar to Acanthamoeba, headache was common 
among GAE and disseminated cases, but vomiting also was high on the list of common 
symptoms, with fever more evident in GAE cases than in disseminated cases.  
Interestingly, unlike Acanthamoeba, infection with Balamuthia was not noted to have any 
symptoms related to sinus problems, nor were there documented cases of Balamuthia 
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rhinosinuitis.  Also there were no standalone cases of cutaneous balamuthiasis, and skin 
manifestations only occurred in cases of disseminated infections.  All disseminated cases 
had granulomatous amebic encephalitis and a second disease manifestation (most often 
skin), whereas disseminated infections of acanthamoebiasis were more varied in their 
manifestations with only 11 of the 30 cases having proven GAE. 
 The generality of signs and symptoms for both Acanthamoeba and Balamuthia 
are reflected in the initial diagnoses.  Although the data were limited, the classical 
diagnoses for headaches and fevers (i.e., meningitis, encephalitis, and 
meningoencephalitis) were not commonly made.  Rather, other diagnoses were more 
common, including: parasitic diseases (e.g., toxoplasmosis, cysticercosis, 
neurocysticercosis), neoplasias, vasculitis, or stroke.  The variables other neurologic 
symptoms, other general symptoms, and other visual symptoms should be more closely 
examined to determine if there any signs or symptoms for these variables that suggest a 
unique symptom for free-living ameba infection. 
Examination of the treatment regimens in survivors of acanthamoebiasis shows 
that while there were several common drugs administered to the survivors, the same 
drugs were used in non-survivors.  A closer examination of the combination of drugs 
used needs to be done to determine if there is a combined therapy that is more effective.  
Balamuthiasis differs in that the two manifestations of the disease reported have always 
involved the central nervous system.  As with acanthamoebiasis, drugs in common usage 
for the survivors were often used in non-survivors.  Again, closer examination of the 
combination of drugs used needs to be done.  Duration and dosage are also important 
factors, but unfortunately much of the dosage information or dosage timing is missing 
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from this retrospective review.  So going forward in data collection for an informal 
surveillance system of free-living amebas, it is essential that accurate treatment 
information is collected for closer examination of whether or not certain drugs are more 
effective than others. 
The mean number of days from illness onset to death for cases of Balamuthia 
mandrillaris was 74 and for Acanthamoeba spp. was 100 days.  This seems to indicate 
that there is sufficient time to make a correct diagnosis, but further evaluation of the data 
is necessary to examine the timing of hospitalization, timing of a correct diagnosis, and 
timing of treatment specific to free-living ameba infection.  If it is determined that 
sufficient time exists for a correct diagnosis, then the question becomes how to increase 
awareness of these infections so they are included in a differential diagnosis when 
patients present with symptoms that tend to be very common to various forms of 
meningitis, and where other potential diagnoses such as toxoplasmosis, 
neurocysticercosis, and tumors are often considered far more quickly. 
Outside of the main research questions, much of the other data explored was 
inconclusive.  The epidemic curve for Acanthamoeba spp. infection shows the highest 
number of cases between 1994 and 1997 with an apparent drop off in reported cases after 
2003.  Because the infection is rare, this is difficult to interpret.  The increase of cases in 
the 1990s is likely due to greater awareness of the infection and increased requests to the 
Centers for Disease Control and Prevention for diagnostic assistance.  Are the cases 
really decreasing, or are other laboratories beginning to perform diagnostic testing and 
therefore CDC is not receiving specimens or reports?  It is important to continue to 
monitor cases to see if there truly is this drop in cases or if the number of infections 
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remains relatively constant over time.  Because Balamuthia was not recognized as the 
cause of human infections until around 1990, the epidemic curve is not particularly 
surprising, with some fluctuations throughout the 1990s and then a seeming increase in 
cases in more recent years, again likely due to greater awareness of free-living ameba 
infections. 
The exposure data were too scarce to draw conclusions from in terms of modes of 
transmission (i.e., water, soil).  While persons with Naegleria fowleri often have a history 
of swimming and recreational water activities in freshwater, persons with Acanthamoeba, 
where exposure history was known, had both water and soil exposures, as did those with 
Balamuthia.  The types of water bodies, water conditions, and recreational water 
activities are data that are not known in these cases. 
The data did strongly support the supposition that Acanthamoeba infection 
disproportionately affect immunocompromised persons.  Outside of those with HIV, it 
appears that steroids and immunosuppressant drugs may be important conditions.  
Although not necessarily associated with immunosuppression, a history of pneumonitis 
also seemed to be common.  This might reflect a compromised portal of entry for the 
pathogens or perhaps pneumonitis is a common co-morbidity in those Acanthmaoeba 
patients with AIDS.  The past medical history for Balamuthia mandrillaris cases is less 
revealing, although drug and alcohol abuse appeared to be a relatively common 
potentially immunosuppressive condition as well as a variety of respiratory conditions. 
 The data exploration for this thesis was limited and the data collected for CDC’s 
informal surveillance system for free-living amebas has more information to be accessed 
and analyzed.  It will be important, as noted above, to look closer at the timing of onset, 
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hospitalization, diagnosis, and death or survival in hope that there may be some 
information that might be useful in improving clinical outcomes.  Because so little data 
on U.S. cases is available, fewer than 200 cases with much missing data, it is crucial to 
gather as much information as possible about exposure, presentation, and treatment of 
future cases.  This exploration has been the first comprehensive look at all known cases 
of Acanthamoeba and Balamuthia infection in 20 years and it contributes to a broader 
understanding of these illnesses. 
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Appendix A: Detailed Tables of All Published Non-Keratitis Acanthamoeba and 
Balamuthia Cases 
 
Table 1: Disseminated Acanthamoebiasis 
Case 
(Ref) 
Yr State Age 
(yr) 
Sex Race 
/Ethnicity 
Health 
Status 
Type of 
Illness 
Clinical 
Course in 
Days* 
Died
121,27,3
1-33 
1972 TX 7 M Black/ 
Unknown 
Pharyngitis, 
water & soil 
exposure 
GAE, 
keratitis 
~44  (s); 
7 (h) 
Y 
26,17,21,
27,34 
1977 CA 24 F Unknown/
Hispanic 
Unknown GAE, skin, 
sinus, lymph 
node, 
adrenals, 
thyroid 
~229 (s); 
 ~49 (h) 
Y 
36,35 1978 UT 57 F Unknown/
Unknown 
Systemic 
lupus 
erthematosu
s 
GAE, lungs, 
skin 
~8 (s); 
~3 (h) 
Y 
46,36 1980 PA 38 M White/ 
Unknown 
Kidney 
transplant 
GAE, skin, 
pulmonary 
hyaline 
membrane 
~43 (h); 
[Possibly 
720 days 
(s)] 
Y 
522,24,3
7-40 
1983 FL 29 M Unknown/
Unknown 
(Haitian) 
AIDS sinus, skin ~138 (s); 
108 (h) 
Y 
66,22,23,
39,41 
1985 CA 34 M Uknown/ 
Unknown 
(Mexican 
American) 
AIDS GAE, skin ~9 (s); 
~2 (h); 
[Possibly 
374 days 
(s)] 
Y 
76,40,42 1987 CA 35 M Black/ 
Unknown 
AIDS, PCP, 
IVDA 
skin, 
keratitis, 
lungs 
~92 after 
diagnosis; 
8 (h)  
Y 
86,24,43 1989 OH 34 M Unknown/ 
Unknown 
AIDS, 
recurrent 
otitis 
skin, sinus ~210 (s) Y 
96,22,23,
44 
1989 IL 38 M White/ 
Unknown 
AIDS, PCP GAE, skin ~24 (h) Y 
1039,45 1990 MA 39 M Unknown/ 
Unknown 
AIDS GAE, lungs ~8 (s); 
4 (h) 
Y 
1122,24,
39,40,46 
1990 PA 7 M Unknown/
Hispanic 
HIV, 
demyelinat-
ing poly-
neuropathy 
skin, sinus ~193 (s) Y 
66 
67 
 
1247 1991 TX 39 F Unknown/ 
Unknown  
CML, bone 
marrow 
transplant, 
pneumonia 
GAE, lungs, 
adrenalitis 
~25 (s) Y 
1322,24,
39,40,48 
1991 OR 33 M Unknown/ 
Unknown 
AIDS, PCP, 
sinusitis 
skin, sinus ~123 (s) 
until 
lesions 
resolved, 
treatment 
con’t for 8 
mo. after 
Y 
1422,40,
42 
1992 CA 47 M Unknown/
Hispanic 
AIDS, PCP, 
HIV wasting 
sickness 
skin, sinus ~120 (h) Y 
1522,40,
42 
1992 CA 36 M American 
Indian/ 
Unknown 
AIDS, PCP skin, sinus ~120 (h) Y 
1640,49 1993 TX .8 M Black/ 
Unknown 
HIV skin, lungs, 
lymph node, 
heart, 
kidney, 
spleen 
~765 (s) Y 
1722,50  1994 Unkn
own 
5 M Black/ 
Unknown 
HIV, PCP skin, osteo-
myelitis 
~810 (s), 
with 
occasional 
skin 
lesions 
recurring 
N 
1822,40,
42 
1994 CA 45 M White/ 
Unknown 
AIDS, PCP, 
chronic 
sinusitis 
skin, sinus, 
bone 
~120 (h) Y 
1922,40,
42 
1994 CA 34 M White/ 
Unknown 
AIDS, PCP, 
chronic 
sinusitis 
GAE, skin, 
sinus 
~111 (s) Y 
2022,34,
47 
1994
? 
TX 32 F Unknown/ 
Unknown 
AML, bone 
marrow 
transplant, 
sinusitis 
GAE, skin ~18 (s) Y 
2151 1995 NY 33 M Black/ 
Unknown 
AIDS, HIV-
related 
cerebral 
atrophy 
skin, sinus ~42 (s); tx 
for another 
150 days 
until death 
Y 
2224,40 1995 MA 37 M Unknown/ 
Unknown 
AIDS skin, sinus Min ~90 (s) Unk
now
n 
2334,52 1997 SC 39 F Black/ 
Unknown 
Lung 
transplant 
skin, liver, 
BAL 
~124 (s); 
118 (h) 
N 
2453 2000 Unkn
own 
37 M Unknown/ 
Unknown 
AIDS, non-
Hodgkins 
lymphoma 
skin, sinus ~131, tx 
continued 
after with 
no 
evidence 
of 
recurrent 
infection 
N 
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2540,54 2000 Unkn
own 
42 M Unknown/ 
Unknown 
AIDS, 
peripheral 
neuropathy 
sinus, lungs ~19 (s); 16 
(h) 
Y 
2655 2001 GA 45 M Unknown/ 
Unknown 
Acute 
myelogenous 
leukemia, 
stem cell 
transplant 
GAE, lung ~98 (s);  
3 (h) 
Y 
2734 2001 MD 61 F Unknown/ 
Unknown 
Kidney 
transplant, 
renal failure 
skin, bone ~26+ (h) Y 
2822,40,
56 
2001 FL 35 F Unknown/
Unknown 
(Nicaragua
n) 
AIDS, 
recurrent 
sinus surgery 
skin, sinus Unknown Y 
2957,58 2003 TX 60 M White/Unk
nown 
Bilateral lung 
transplant; 
water 
exposure 
GAE, skin, 
lung 
~38 (s); 17 
(h) 
Y 
*Clinical course may mean from symptom onset until death or resolution of illness (s) or from 
presentation/hospitalization until death or resolution of illness (h). 
AIDS = Acquired Immune Deficiency Syndrome; HIV = Human Immunodeficiency Virus; PCP = 
Pneumocystis carinii pneumonia, IVDA = intravenous drug abuse; CML = chronic myelogenous 
leukemia; AML = acute myeloid leukemia 
 
Table 2: Disseminated Balamuthiasis 
Case 
(Ref) 
Yr State Age 
(yr) 
Sex Race/ 
Ethnicity 
Health 
Status 
Type of 
Illness 
Clinical 
Course 
in Days 
Died 
16,17,59 1975 LA 56 M Black/ 
Unknown 
Alcohol 
misuse, 
G6PD 
GAE, 
pancreas 
~27 (s); 
13 (h) 
Y 
26,16,23,
60,61 
1985 NY 36 M Unknown/ 
Unknown 
HIV, IVDA GAE, 
kidney, 
adrenals 
~25 (s); 
~18 (h) 
Y 
316,23 1989 GA 52 M Unknown/ 
Unknown 
Amputation, 
soil exposure 
GAE, 
cutaneous 
~101 (s); 
 ~77 (h) 
Y 
462 1996 CA 64 M White/ 
Unknown 
Ankylosing 
spondylitis, 
gardening 
GAE, 
cutaneous 
Unknown N 
563 1999 CA 2 F Unknown/
Hispanic 
Otitis media GAE, lungs ~24 (s); 9 
(h) 
Y 
664 1999 TX 38 M Unknown/
Hispanic 
IVDA GAE, 
cutaneous 
~568 (s); 
19 (h) 
Y 
765 1999 TX 89 M Unknown/ 
Unknown 
Coronary 
artery 
disease, mild 
congestive 
heart failure 
CSF, 
cutaneous 
~390 (s); 
13 (h) 
Y 
*Clinical course may mean from symptom onset until death or resolution of illness (s) or from 
presentation/hospitalization until death or resolution of illness (h). 
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HIV = Human Immunodeficiency Virus ; G6PD = glucose-6-phospate dehydrogenase deficiency; 
IVDA = intravenous drug abuse 
 
Table 3: Acanthamoeba GAE 
Case 
(Ref) 
Yr State Age 
(yr) 
Sex Race/ 
Ethnicity 
Health Status Clinical 
Course in 
Days 
Died 
16,17,21,26,
27 
1955 AZ 6 F Unknown/ 
Unknown 
Unknown ~252 (s); 
16 (h) 
Y 
266 1964 TX 59 M Unknown/ 
Unknown 
Drug abuse, 
cirrhosis 
21 (h) Y 
36,17,27,67 1971 PA 58 M Unknown/ 
Unknown 
Alcohol abuse, 
pneumonia, water 
exposure 
~21 (h) Y 
46,27,68 1971 NY 57 M Unknown/ 
Unknown 
History of stroke, 
intestinal 
amebiasis, water 
exposure 
Unknown Y 
56,14,15,17,
27 
1972 NY? 27 M White/ 
Unknown 
Hodgkins, long-
term immune-
suppression, mild 
respiratory 
infections 
31 (s); 
5 (h) 
Y 
66,17,21 1976 LA 32 F White/ 
Unknown 
Pneumonitis ~43 (s) Y 
76 1978 NY 11 F Unknown/ 
Unknown 
Unknown, soil 
exposure 
Unknown Y 
86 1978 TX 2 F Unknown/ 
Unknown 
Unknown Unknown Unknown 
96,22,23 1981 GA 31 F Unknown/ 
Unknown 
Mixed connective 
tissue disorder 
~40 (s); 
9 (h) 
Y 
106,23,39,6
9 
1985 CA 34 M Unknown/ 
Unknown 
HIV, PCP ~35 (s); 
~28 (h) 
Y 
116,23,39 1987 GA 34 M Unknown/
Uknown 
AIDS, PCP 8 (s); 4 (h) s 
126 1988 MN 60 M Unknown/
Unknown 
Unknown Unknown Unknown 
136 1988 SC 38 M Unknown/
Unknown 
Unknown Unknown Unknown 
1423,39 1990 GA 34 M Unknown/
Unknown 
AIDS, PCP ~15 (s); 8 (h) Y 
1570 1997
? 
NM 35 M Unknown/
Unknown 
IVDA, alcohol 
abuse 
~11 (s) Y 
1671 1997 CT 47 F Unknown/
Unknown 
Moncytoid B cell 
lymphoma, stem 
cell transplant 
~143 (s); 
11 (h) 
Y 
1772 2003 PA 40 M Unknown/
Unknown 
Multiple visceral 
transplant, 
immune-
suppressants 
~14 (s); 
12 (h) 
Y 
1873,74 2003 TN 70 F White/ 
Unknown 
Discoid lupus 
erthematosus 
~99 (s); 
63 (h) 
Y 
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1975 2004 Unkn
won 
51 M White/ 
Unknown 
Kidney transplant, 
diabetes, potential 
water exposure 
~54 (s) Y 
2076 2005 VA 41 M Black/ 
Unknown 
HIV ~9 (s) Y 
2177 2006
? 
MA 24 F Unknown/
Unknown 
Systemic lupus 
erythematosus, 
drug and alcohol 
dependency 
~120 (s); 
60 (h) 
Y 
*Clinical course may mean from symptom onset until death or resolution of illness (s) or from 
presentation/hospitalization until death or resolution of illness (h). 
AIDS = Acquired Immune Deficiency Syndrome; HIV = Human Immunodeficiency Virus; PCP = 
Pneumocystis carinii pneumonia, IVDA = intravenous drug abuse 
 
Table 4: Balamuthia GAE 
Case 
(Ref) 
Yr State Age 
(yr) 
Sex Race/ 
Ethnicity 
Health 
Status 
Clinical Course 
in Days 
Died 
16,17,27,
28 
1974 VA 47 F Black/ 
Unknown 
Diabetes, 
well water 
~21 (s); 7 (h) Y 
26,16,78,
79 
1978 SC .4 M White/ 
Unknown 
Seizure 
activity, 
pneumonia 
~35 (s); 5 (h) Y 
36,16,79,
80 
1979 PA 2.5 M Unknown/ 
Unknown 
Unknown 240 (s) Y 
46,16,79 1982 CA .8 F Unknown/ 
Unknown 
Unknown 15 (s) Y 
56,16 1983 FL 61 M Unknown/ 
Unknown 
Alcohol 
misuse, TB 
112 (s) Y 
66 1984 CA 72 M Unknown/ 
Unknown 
Unknown Unknown Y 
76,16,79,
81 
1986 TX 11 F Unknown/ 
Hispanic 
Healthy, soil 
exposure 
150 (s) Y 
816 1990 NV 60 M Unknown/ 
Unknown 
Alcohol 
misuse 
Unknown Y 
982 1990 NC 1.5 M Unknown/ 
Unknown 
Unknown, 
water 
exposure 
~23 (h) Y 
1083 1991 TX .11 F Unknown/ 
Hispanic 
Healthy ~28 (s) Y 
1184 1991 NV .6 F Unknown/ 
Unknown 
Otitis, 
pharyngitis 
~25 (h) Y 
1279 1992 AZ 13 F Unknown/ 
Unknown 
Healthy ~16 (s) Y 
1385 1993 TX 5 M White/ 
Unknown 
Healthy ~57 (s) Y 
1479 1993 AZ 2.3 M Unknown/ 
Unknown 
Otitis ~23 (s) Y 
1585 1993 TX 15 M Unknown/ 
Hispanic 
Healthy ~72 (s) Y 
1686 1995 MD 34 F Unknown/ 
Unknown 
HIV ~24 (h) Y 
1787,88 1996 CA 32 M Unknown/ IVDA, ~42 (s) Y 
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Hispanic alcohol 
misuse 
1889 1996 CO 3 M Unknown/ 
Unknown 
Pharyngitis ~17 (s) Y 
1990 1999 MA 52 F Unknown/ 
Unknown 
Chronic 
sinus 
infections, 
chronic 
idiopathic 
neutropenia 
~105 (s) Y 
2091 1999 VT 5 F Unknown/ 
Unknown 
Healthy, 
water 
exposure 
75 (h) Y 
2162,88 2000 CA 5 F Unknown/ 
Hispanic 
Healthy ~485 (h); multiple 
hospitalizations 
N 
227,8,63
,92,93 
2001 CA 3 F White/ 
Hispanic 
Otitis ~24 (s) Y 
2363 2001 TX 2 M Unknown/ 
Hispanic 
Unknown Unknown Y 
2463,93,
94 
2001 CA 7 M Unknown/ 
Hispanic 
Unknown ~45 (s) Y 
2593 2002 CA 64 M Unknown/ 
Hispanic 
Unknown, 
occupational 
soil 
exposure 
~8 (s) Y 
2695 2002 FL 40 M Unknown/ 
Unknown 
Alcohol and 
drug abuse 
~10 (h) Y 
2796 2002 NY 72 F Unknown/ 
Unknown 
Healthy, soil 
exposure 
~27 (s) N 
2893,94 2003 CA 7 M Unknown/ 
Hispanic 
Steroid 
therapy 
3 (h) from final 
hospitalization 
Y 
2993 2005 CA 19 M Unknown/ 
Hispanic 
Former drug 
abuse 
8 (h) Y 
3093 2005 CA 12 M Unknown/ 
Hispanic 
Unknown, 
soil 
exposure 
120 (h) Y 
3193 2007 CA 35 M Unknown/ 
Hispanic 
Unknown Unknown N 
3297 2007 KY 2 M Unknown/ 
Unknown 
Healthy ~62 (h) N 
3393,98 2007 CA 43 M White/ 
Unknown 
Pneumonia, 
idiopathic 
thrombo-
cytopenic 
purpura, 
occupational 
soil 
exposure 
~117 (s) Y 
3499 2007 Unkno
wn 
Unk
now
n 
Unk
now
n 
Unknown/ 
Unknown 
Multiple 
visceral 
organ 
transplant 
Unknown Y 
3593 2007 CA 72 M Pacific 
Islander/ 
Unknown 
Unknown, 
gardening 
7 (h) Y 
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3693 2008 CA 1.6 M Unknown/ 
Hispanic 
Unknown 35 (h) Y 
3718 2009 MS 4 M Unknown/ 
Unknown 
Influenza A, 
water & soil 
exposure 
~12 (s) Y 
3818 2009 MS 31 F Unknown/ 
Unknown 
Kidney 
transplant 
~55 d (s) Y 
3918 2009 MS 27 M Unknown/ 
Unknown 
Kidney 
transplant 
~139 (s) N 
*Clinical course may mean from symptom onset until death or resolution of illness (s) or from 
presentation/hospitalization until death or resolution of illness (h). 
TB = Tuberculosis; HIV = Human Immunodeficiency Virus; IVDA = intravenous drug abuse 
Table 5: Cutaneous acanthamoebiasis 
Case 
(Ref) 
Yr State Age 
(yr) 
Sex Race/ 
Ethnicity 
Health Status Clinical Course 
in Days 
Died 
16,22,39,1
00 
1989 NY 38 M Unknown/ 
Unknown 
HIV, 
pneumonia 
>21 (s) Y 
222,23,39,
44 
1990 IL 60 M Unknown/ 
Hispanic 
AIDS, PCP ~40 (s) Y 
322,39,40 1991 CA 30 M Unknown/ 
Unknown 
AIDS, PCP, 
chronic 
sinusitis 
~77 (s) Y 
439,101 1991 VA 42 M Unknown/ 
Unknown 
AIDS 42 (s) Y 
522,34,102 1992 NY 31 M Unknown/ 
Unknown 
ESRD, Kidney 
transplant, 
diabetes 
~420 (s), con’t 
treatment after 
lesions resolved 
N 
622,103 1994 DC 44 M Unknown/ 
Unknown 
AIDS, 
progressive 
myelitis, 
peripheral 
neuropathy, 
water exposure 
~450 (s) Y 
722,40,104 1995
? 
CA 38 M White/ 
Unknown 
AIDS, PCP, 
chronic 
sinusitis, water 
exposure 
Unknown Y 
822,105 1996 CA 27 F Unknown /
Hispanic 
AIDS ~240 (s) Y 
922,106 1997
? 
MI 44 M Unknown/ 
Unknown 
AIDS, TB ~180 (s) Y 
1022,106 1997
? 
MI 38 M Unknown/ 
Unknown 
AIDS ~62 (s) Y 
11107 2003 MD 51 F Unknown/ 
Unknown 
AIDS, PCP ~31 (s) N 
12108 2004 CA 52 F Unknown/ 
Unknown 
Lung 
transplant, 
immune- 
Suppressants, 
creek as 
drinking water 
source 
~150 (h) N 
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*Clinical course may mean from symptom onset until death or resolution of illness(s) or from 
presentation/hospitalization until death or resolution of illness (h). 
AIDS = Acquired Immune Deficiency Syndrome; HIV = Human Immunodeficiency Virus; PCP = 
Pneumocystis carinii pneumonia, ESRD = end-stage renal disease; TB = Tuberculosis 
 
Table 6: Acanthamoeba Rhinosinusitis 
Case 
(Ref) 
Yr State Age 
(yr) 
Sex Race/ 
Ethnicity 
Health Status Clinical 
Course in 
Days 
Died 
153 1994 Unk 45 M Unknown/ 
Unknown 
HIV, chronic sinusitis Unknown N 
2109 2005 FL 49 F Unknown/ 
Unknown 
Bilateral lung 
transplant, immuno-
suppressants, 
steroids 
Unknown N 
*Clinical course may mean from symptom onset until death or resolution of illness (s) or from 
presentation/hospitalization until death or resolution of illness (h). 
HIV = Human Immunodeficiency Virus 
 
Table 7: Acanthamoeba osteomyelitis 
Case 
(Ref) 
Yr State Age 
(yr) 
Sex Race/ 
\Ethnicity 
Health 
Status 
Clinical Course in 
Days 
Died 
1110 1979 PA 32 F White/ 
Unknown 
Suspected 
diabetes 
Unknown N 
*Clinical course may mean from symptom onset until death or resolution of illness (s) or from 
presentation/hospitalization until death or resolution of illness (h). 
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Date of Report:                        
Demographics 
Patient’s Last Name                                       First                                            M.I. 
                                                                                                                
      
Age 
      
Gender: 
Male     Female     Unknown 
Ethnicity: 
Hispanic       Unknown 
Non-Hispanic 
Race: 
White 
Black   
 
Asian/Pacific Islander
American Indian 
           
Unknown    
Other __       
 
County and State of Residence:  _     _________________ 
County and State of Treatment:    __     ________________ 
Immigrant?   Yes    No  □  Unknown               Country of origin: _____     ___       
Length of time since immigrated: _____________ 
   Occupation:  ____     _________ 
 
Exposure History 
County/State of Suspected Exposure:                     /                          Number of persons exposed (if known):                 
 
Source of possible exposure, if known:       (please check all that apply and provide best estimates of dates) 
Type: Date(s): Type: Date(s): Type: Date(s): 
  Canal                      __     __    Private Club Pool __     __     Community Pool __     __  
  Lake          __     __    Private Home Pool __     __     Apartment Pool __     __  
  Pond __     __    Fill-and-Drain Pool __     __     Fountain __     __  
  Ocean __     __    Hotel Pool __     __     Water park __     __ 
  River/Stream __     __    Spring (hot/cold) __     __     
  Well __     __    Spa/hot tub/whirlpool __     __     
Water 
Exposures 
 Yes 
 No 
 Unknown 
 
If “yes”, please 
fill out section on 
right   
  Other, specify   ___________________________            Date(s):       
                                      Yes    No    Unknown                                                    Yes    No    Unknown 
Diving into water                Snorkeling/scuba diving         
Inhaled water         Swimming         
Jumped into water         Water sports (skiing etc.)         
Swallowed water         Wore nose clip or plugged 
nose when jumping/diving         
Water Activities 
 Yes   
 No  
 Unknown 
If “yes”, please 
fill out specifics 
on right 
Splashed water         Other, specify                                                          
Type:      Date(s):  
  Gardening   __     __      Farmer/rancher 
  Composting   __     __      Firefighter 
  Farm/Ranch   __     __      Lifeguard/pool attendant 
Soil Exposures 
 Yes   
 No  
 Unknown 
If “yes”, please 
fill out specifics 
on right 
  Other, specify: _____             Date(s):     __ 
Occupational  
Exposures 
 Yes   
 No  
 Unknown 
If “yes”, please 
fill out specifics 
on right 
   Other, specify: _________      
 
 
Route of Entry if 
known:        
Other, specify:                                Inhalation Contact  
(please check all that 
apply) 
 
 
If Water Source , Please List Source Characteristics: 
Name of Water Exposure:                                              Geospatial Coordinates:                                   Thermally Polluted:  Y / N 
Size of Body Water: □ < 10 acres 
□ 10-100 acres □ >100 acres 
□ Unknown 
Water Turbidity:  □ Clear           □ 
Cloudy  □ Murky  □ Unknown 
Water level:  □ Low □ High 
□ Normal □ Flood Stage      
□ Unknown 
Flow Rate:  □ Slow  
□ Normal □ Fast 
□ Unknown 
Ambient Air Temperature:     F/C Water Temperature:  ___F/C Depth:  __     __   
 Ingestion  Via Wound   
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Travel History last 2 years:     Yes  No  Unknown   If yes, please specify in table below: 
Locations Dates (from – to) 
           
           
           
Past Medical History:  
Please check all conditions/symptoms that patient has currently or has had within past 2 years: 
Treatment/drugs:                                                      HIV/AIDS: 
 
ENT/Respiratory: Other Conditions: 
 Otitis  Sinusitis Dermatitis 
 Rhinitis  Epistaxis Skin infections 
 Broken Nose  Nasal Surgery Eye infection 
 Deviated septum  Pharyngitis Other, specify: ________________________ 
 Tuberculosis  Pneumonitis Injury, specify: ________________________ 
  Other lung disease, specify:             
                          
  
Current Illness 
Date of Illness onset:                                           Duration of illness: (in days)       
Was patient admitted to hospital for current illness?    Yes  No  Unknown 
If Yes, Date of most recent hospitalization:                            Duration of most recent hospitalization (in days):        
 
Hospital Name:___                  City:___     _____________                   State:       __ 
Physician Name 1:___     _____________         E-mail (if avail): ___     __________      Phone: ___     ____          
Physician Name 2:___     _____________         E-mail (if avail): ___     __________      Phone: ___     ____          
Other Recent Hospitalizations: Yes  No Unknown
   
Dates (from- to) Diagnosis 
  
  
HIV  Yes  No  Unknown
AIDS  Yes  No  Unknown 
On 
Antiretrovirals 
 Yes  No  Unknown 
Excessive antibiotic use (specify in Provider 
comments)  
 
Illegal drug use, specify:__     _________   
 Immunosuppressants 
 Radiation therapy 
 Steroid use 
Other Immunocompromised Conditions                
Alcohol misuse            Diabetes mellitus  
G6PD deficiency         Liver cirrhosis  
Malnourishment          Pregnancy (recent)  
Renal failure               Lymphoproliferative disease 
 Systemic Lupus Erythematosus (SLE)  
 Cancer, 
specify:______________________________ 
 Other hematologic disease, specify: 
______________ 
 Other autoimmune disease, specify: 
______________ 
 Organ transplant, specify: 
______________________ 
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History of Present Illness:  
Please provide a brief description of the patient’s clinical course, prior to hospitalization: 
 
 
Signs/Symptoms on Presentation (most recent hospitalization):  
Vital 
Signs:_________________________________________________________________________________________
_ 
Temperature: _     _ F / C P: _     _ bpm     R= __     _breaths/min    BP: 
_     ___mmHg 
 
General:_____________________________________            ______            Visual______________________ 
 Duration  (days)  
 Duration  
(days) 
 Duration  
(days) 
 Fever        Myalgia       Blurred vision       
 Nausea        Back Pain       Diplopia       
 Vomiting        Cough       Photophobia                          
 Diarrhea        Shortness of breath       
 Weight loss        Sinus problems       
Other visual changes, specify:  
      _________            
 Anorexia        Abnormal reflexes       
 Headache        Disorientation       
 Stiff neck        Lethargy/fatigue       
       Other general symptom/sign, specify:_     ________ 
 
Neurologic:_______________________________________________________________________________________
___ 
  Duration (days)  
 Duration 
(days) 
  Duration 
(days) 
 Altered mental status        Dysphagia       Weakness       
  Aphasia        Facial numbness/Parathesia       Hemiparesis/Hemiplegia       
  Ataxia        Hallucinations       Altered sense of taste       
 Behavioral changes        Combativeness       Altered sense of smell       
 Coma        Hyperreflexia       Decerebrate posturing       
 Confusion        Loss of balance       Decorticate posturing       
 Cranial nerve VI deficit        Numbness       Fixed, nonreactive pupils       
 
Skin Lesions:    Yes  No       Unknown      If yes, please specify in table below:
 
Lesion type Anatomic location Size Number Duration (days) 
Ulcers     
Plaques     
Erythematous nodules     
Other     
 
Other Symptoms/Signs: 
 Other, specify:_     ______________________ 
 Cranial nerve VII deficit        Seizures       Dilated pupils       
 Cranial nerve XII deficit        Upgoing toes       Nystagmus       
  Other cranial nerve deficit,  specify:                    ______     Duration:        
Other neurologic deficit,  
specify:                                 Duration:        
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Signs/Symptoms developed while in hospital:  
 
General:___________________________________________   Visual 
:__________________________________ 
 Fever  Myalgia Blurred vision 
 Nausea  Back Pain Diplopia 
 Vomiting  Cough Photophobia 
Other visual changes, specify:_     _______  Diarrhea  Shortness of breath 
 Weight loss  Sinus problems   
 Anorexia  Abnormal Reflexes 
 Headache  Disorientation 
 Stiff neck  Lethargy/fatigue 
Other general symptom/sign, specify:_     __________  
 
    
Neurologic:_______________________________________________________________________________________
___ 
 Altered mental status Dysphagia  Altered sense of taste 
  Aphasia Facial numbness/Parathesia  Altered sense of smell 
  Ataxia Hallucinations  Decerebrate posturing 
 Behavioral changes Hemiparesis/Hemiplegia  Decorticate posturing 
 Coma Hyperreflexia  Fixed, nonreactive pupils 
 Combativeness Loss of balance  Dilated pupils 
 Confusion Numbness  Nystagmus 
 Cranial nerve VI deficit Seizures 
 Cranial nerve VII deficit Upgoing toes 
 Cranial nerve XII deficit Weakness 
Other neurologic deficit, specify:  _____     ________   Other Cranial nerve deficit, specify:                        
 
Skin Lesions:    Yes  No            If yes, please specify in table below: 
 
Lesion type Anatomic location Size Number 
Ulcers    
Plaques    
Erythematous nodules    
Other    
Other Symptoms/Signs: 
 
 Other, specify:_     ______________________ 
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Diagnostic Tests: Note please provide dates when possible. If date not available, provide hospital day (i.e. CSF tap on Hosp. Day 2) 
 
LABORATORY TESTING 
 
CSF Date________________ Date_______________ Date_______________ 
 Results Results Results 
Opening pressure (mmH2O)                   
WBC count (per mm3 )                   
RBC count (per mm3 )                   
Neutrophil %                   
Monocyte %                   
Lymphocyte %                   
Bands %                   
Eosinophil %                   
Protein (mg/100ml)                   
Glucose (mg/100ml)                   
Cytokines                   
CSF Culture: *                   
CSF PCR: *                   
CSF latex agglutination: *                    
CSF mount:  
Please indicate preparation 
type and findings, if any 
 Centrifuged    Stained      
  Wet               
Amebae present?   Y     N  
 Centrifuged    Stained      
  Wet               
Amebae present?   Y     N  
 Centrifuged    Stained      
  Wet               
Amebae present?   Y     N  
 * Please provide results for all bacteria, viral and/or parasitic testing.  
 Presenting Lab Values:       Date:                      Cultures for Free Living Amebae:                                                                                       
 Results   Source Date                           Result 
RBC count (per mm3 )     Negative   + Balamuthia 
Hematocrit %   
 Blood  
  + Naegleria   + Acanthamoeba 
WBC count (per mm3 )     Negative   + Balamuthia 
Neutrophil %   
 Skin  
  + Naegleria   + Acanthamoeba 
Lymphocyte %     Negative   + Balamuthia 
Monocyte %   
 Brain  
  + Naegleria   + Acanthamoeba 
Eosinophil %     Negative   + Balamuthia 
Bands %   
 Abscess  
  + Naegleria   + Acanthamoeba 
CD4 count (per mm3)     Negative   + Balamuthia 
Protein (mg/100ml)   
 Other, specify:  
                  
 
  + Naegleria   + Acanthamoeba 
   
Sodium (mEq/L)   
Potassium (mEq/L)   
Chloride (mEq/L)   
Bicarbonate (mEq/L)   
 
PCR for Free Living Amebae:                       BUN (mg/100ml)   
Creatinine (mg/100ml)    Source Date Result 
Glucose (mg/100ml)     Negative   + Balamuthia 
   
 Blood 
 
 
  + Naegleria   + Acanthamoeba 
Serology:     Negative   + Balamuthia 
Date Result  
 Skin  
  + Naegleria   + Acanthamoeba 
     Negative   + Balamuthia 
   
 Brain 
 
 
  + Naegleria   + Acanthamoeba 
     Negative   + Balamuthia 
   
 Abscess 
 
 
  + Naegleria   + Acanthamoeba 
     Negative   + Balamuthia 
   
 Other, specify:  
                  
 
  + Naegleria   + Acanthamoeba 
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HISTOPATHOLOGY 
Brain biopsy:             Yes  No  Unknown 
 
 Date:       Date:       
Location             
Timing   Antemortem   Postmortem   Unknown   Antemortem   Postmortem   Unknown 
   Amebic trophozoites    Amebic trophozoites 
   Amebic cysts    Amebic cysts 
   Ameba, not specified    Ameba, not specified 
   Hemorrhage    Necrosis    Hemorrhage    Necrosis 
   Encephalomalacia    Edema    Encephalomalacia    Edema 
   Abscess    Vasculitis    Abscess    Vasculitis 
   Perivascular Inflammation    Perivascular Inflammation 
   Thrombosis    Thrombosis 
   Neovascularization    Neovascularization 
   Neutrophillic inflammation / infiltrate    Neutrophillic inflammation / infiltrate 
   Lymphocytic inflammation / infiltrate    Lymphocytic inflammation / infiltrate 
   Granulomatous inflammation    Granulomatous inflammation 
   Granuloma    Granuloma 
   Meningitis    Encephalitis    Meningitis    Encephalitis 
Results 
(check all that 
apply) 
   Meningoencephalitis    Meningoencephalitis 
Other Results/ 
Comments 
  
 
Skin biopsy:               Yes  No  Unknown 
 
 Date:       Date:       
Location             
Timing   Antemortem   Postmortem   Unknown   Antemortem   Postmortem   Unknown 
Results      No amebae seen 
     Amebic trophozoites 
     Amebic cysts 
     Amebae, not specified 
     No amebae seen   
     Amebic trophozoites 
     Amebic cysts 
     Amebae, not specified 
Other Results/ 
Comments 
  
 
Sinus biopsy:             Yes  No  Unknown 
  
 Date:       Date:       
Location             
Timing   Antemortem   Postmortem   Unknown   Antemortem   Postmortem   Unknown 
Results      No amebae seen 
     Amebic trophozoites 
     Amebic cysts 
     Amebae, not specified 
     No amebae seen   
     Amebic trophozoites 
     Amebic cysts 
     Amebae, not specified 
Other Results/ 
Comments 
  
 
Other biopsy results:       
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DIAGNOSTIC IMAGING 
CT:  Date of First CT:        
Lesion location:    (please check all that apply) 
 Basal Ganglia  Left Occipital  Left Temporal 
 Brainstem  Right Occipital  Right Temporal 
 Right Cerebellum  Left Parietal   Thalamus 
 Left Cerebellum  Right Parietal  Other, specify:_     ______________ 
 Left Frontal  Pons   
 Right Frontal  Spinal Cord   
 
Lesion:       (please check all that apply)   
 
Addition
al 
Descript
ion, if 
needed: 
      
 Abscess Hyperdense   Enhancing 
 Edema Hypodense  Ring enhancing 
 Erosion Infarcts  Sinusitis 
 Hemorrhage Mass  Ventriculomegaly 
 Herniation Multifocal lesions  Other, specify: __     _______________ 
 
Please list dates of subsequent CT scans and changes noted:  
Date Findings 
            
 
            
 
            
 
 
 
MRI:  Date of First MRI:        
Lesion location:    (please check all that apply) 
 Basal Ganglia  Left Occipital  Left Temporal 
 Brainstem  Right Occipital  Right Temporal 
 Right Cerebellum  Left Parietal   Thalamus 
 Left Cerebellum  Right Parietal  Other, specify:_     ______________ 
 Left Frontal  Pons   
 Right Frontal  Spinal Cord   
 
Lesion:       (please check all that apply)   
 
Addition
al 
Descript
ion, if 
needed: 
      
 Abscess Hyperdense   Enhancing 
 Edema Hypodense  Ring enhancing 
 Erosion Infarcts  Sinusitis 
 Hemorrhage Mass  Ventriculomegaly 
 Herniation Multifocal lesions  Other, specify: __     _______________ 
 
Please list dates of subsequent MRI scans and changes noted:  
Date Findings 
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Diagnosis: 
 
Admitting diagnosis:   Date of Diagnosis:                               
 Encephalitis  Meningoencephalitis 
 Meningitis  Other, Specify _     ____________ 
 
Final diagnosis:                  Date of Diagnosis:                               
 GAE (Acanthamoeba spp.)  GAE (Balamuthia mandillaris) PAM (Naegleria fowleri) 
 Disseminated Acanthamoebiasis  Disseminated Balamuthiasis Other, specify:       
 Acanthamoeba rhinosinusitis  Balamuthia rhinosinusitis   
 Cutaneous acanthamoebiasis  Cutaneous balamuthiasis   
 
Diagnosis Method: 
Indirect Immunofluorescence (IIF)   Antemortem   Postmortem  Unknown  
PCR   Antemortem   Postmortem  Unknown  
Histopathology   Antemortem   Postmortem  Unknown  
CSF Wet Mount   Antemortem   Postmortem  Unknown  
Culture   Antemortem   Postmortem  Unknown  
Other, Specify:         Antemortem   Postmortem  Unknown  
 
Treatment: 
 
Surgical resection:     Yes  No 
 
Medications:  (please check all that apply)   
 Acyclovir  Ethambutol  Rifampin 
 Albendazole  Fluconazole  Steroid,  specify__  ___      
 Amikacin  Flucytosine  Streptomycin 
 Amphotericin B  Isoniazid  Sulfonamide, specify______      
 Amphotericin B lipid  Itraconazole  Sulfadiazine 
 Amphotericin B liposomal  Ketoconazole  Topical Chlorhexidine 
 Azithromycin  Mannitol  Trimethoprim/sulfa 
 Ceftriaxone  Metronidazole  Voriconazole 
Other, specify____     ____  Ciprofloxacin  Miconazole  
 Chloramphenicol  Miltefosine  Other, specify____     ____ 
 Clarithromycin  Ornidazole  Other, specify____     ____ 
 Co-trimoxazole  Pentamidine  Other, specify____     ____ 
 Dexamethasone  Pyrimethamine  Other, specify____     ____ 
 
If you checked any of the medications listed above, please list below with the start and stop dates, doses, 
frequencies, and routes of administration. If an individual drug was given using multiple doses, over multiple 
dates, and/or given by multiple routes, please indicate this in the rows below.  
Medication Start date: Stop date: Dose and Frequency Route of Administration 
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Other therapies: (please check all that apply)   
  Start date: Stop date: 
 IV fluids             
 Total Parenteral Nutrition (TPN)             
 Dialysis for renal failure             
 Other, specify_____________             
 Other, specify_____________             
 Other, specify_____________             
 
 
Outcome: 
 
Survived?   
 
Yes  No  Unknown 
 
 If survived:  Residual neurologic deficits?   
 
Yes No Unknown
 
If Yes, Please describe neurologic deficits: __     ____________________________________________________ 
 
Date of discharge:                  OR            Date of death:       
 
If died:  Cause of death:  
   
 
 
 Brain death  Removed life support 
 Cardiorespiratory failure  Other, specify:_     ___________________ 
 Herniation 
If died: Organs transplanted?  Yes  No 
 
If yes, which ones:     _________________________________ 
 
Please provide a brief description of the patient’s clinical course, complications, and any additional comments: 
 
 
 
 
CDC USE ONLY: 
1st DASH #       
2nd DASH #       
3rd DASH #       
4th DASH #       
5th DASH #       
List additional  
DASH #s: 
                     
                
 
Case report citation 1       
Case report citation 2       
List additional case citations 
 
      
 
Calculated durations: 
Incubation period (days):       
Illness Onset to Admission (days):          
Illness Onset to Death (days):       
Exposure to Death (days):       
Clinical Stage at presentation: ______
 
 
Appendix C: Epidemic Curves for Acanthamoeba and Balamuthia Cases 
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Appendix D: Treatment Regimens for Survivors 
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Survivors of disseminated 
acanthamoebiasis 
Survivors of cutaneous 
acanthamoebiasis 
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Survivors of Acanthamoeba rhinosinusitis  
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Survivor of 
disseminated 
balamuthiasis  
Survivors of Balamuthia GAE 
